Bacterial sliding clamp inhibitors that mimic the sequential binding mechanism of endogenous linear motifs by Yin, Zhou et al.
University of Wollongong
Research Online
Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health
2015
Bacterial sliding clamp inhibitors that mimic the
sequential binding mechanism of endogenous
linear motifs
Zhou Yin
University of Wollongong, zy877@uowmail.edu.au
Louise R. Whittell
University of Wollongong, lwhittel@uow.edu.au
Yao Wang
University of Wollongong, yw974@uowmail.edu.au
Slobodan Jergic
University of Wollongong, jergic@uow.edu.au
Cong Ma
University of Newcastle
See next page for additional authors
Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au
Publication Details
Yin, Z., Whittell, L. R., Wang, Y., Jergic, S., Ma, C., Lewis, P. J., Dixon, N. E., Beck, J. L., Kelso, M. J. & Oakley, A. J. (2015). Bacterial
sliding clamp inhibitors that mimic the sequential binding mechanism of endogenous linear motifs. Journal of Medicinal Chemistry,
58 (11), 4693-4702.
Bacterial sliding clamp inhibitors that mimic the sequential binding
mechanism of endogenous linear motifs
Abstract
The bacterial DNA replication machinery presents new targets for the development of antibiotics acting via
novel mechanisms. One such target is the protein-protein interaction between the DNA sliding clamp and the
conserved peptide linear motifs in DNA polymerases. We previously established that binding of linear motifs
to the Escherichia coli sliding clamp occurs via a sequential mechanism that involves two subsites (I and II).
Here, we report the development of small-molecule inhibitors that mimic this mechanism. The compounds
contain tetrahydrocarbazole moieties as "anchors" to occupy subsite I. Functional groups appended at the
tetrahydrocarbazole nitrogen bind to a channel gated by the side chain of M362 and lie at the edge of subsite
II. One derivative induced the formation of a new binding pocket, termed subsite III, by rearrangement of a
loop adjacent to subsite I. Discovery of the extended binding area will guide further inhibitor development.
Disciplines
Medicine and Health Sciences | Social and Behavioral Sciences
Publication Details
Yin, Z., Whittell, L. R., Wang, Y., Jergic, S., Ma, C., Lewis, P. J., Dixon, N. E., Beck, J. L., Kelso, M. J. & Oakley,
A. J. (2015). Bacterial sliding clamp inhibitors that mimic the sequential binding mechanism of endogenous
linear motifs. Journal of Medicinal Chemistry, 58 (11), 4693-4702.
Authors
Zhou Yin, Louise R. Whittell, Yao Wang, Slobodan Jergic, Cong Ma, Peter Lewis, Nicholas E. Dixon, Jennifer
L. Beck, Michael J. Kelso, and Aaron J. Oakley
This journal article is available at Research Online: http://ro.uow.edu.au/smhpapers/2890
 1
Bacterial Sliding Clamp Inhibitors that Mimic the Sequential Binding Mechanism 
of Endogenous Linear Motifs  
Zhou Yin,†,# Louise R. Whittell,†,# Yao Wang,† Slobodan Jergic,† Cong Ma,‡ Peter J. Lew-
is.‡ Nicholas E. Dixon,† Jennifer L. Beck,† Michael J. Kelso,† and Aaron J. Oakley*,† 
†School of Chemistry and Centre for Medical and Molecular Bioscience, The University 
of Wollongong, and The Illawarra Health and Medical Research Institute, Wollongong, 
New South Wales 2522, Australia 
‡School of Environmental and Life Sciences, The University of  Newcastle, Callaghan, 
New South Wales 2308, Australia 
ABSTRACT: The bacterial DNA replication machinery presents new targets for the de-
velopment of antibiotics acting via novel mechanisms. One such target is the protein–
protein interaction between the DNA sliding clamp and the conserved peptide linear mo-
tifs in DNA polymerases. We previously established that binding of linear motifs to the 
Escherichia coli sliding clamp occurs via a sequential mechanism that involves two sub-
sites (I and II). Here, we report the development of small-molecule inhibitors that mimic 
this mechanism. The compounds contain tetrahydrocarbazole moieties as "anchors" to 
occupy subsite I. Functional groups appended at the tetrahydrocarbazole nitrogen bind to 
a channel gated by the sidechain of M362 and lie at the edge of subsite II. One derivative 
induced the formation of a new binding pocket, termed subsite III, by rearrangement of a 
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loop adjacent to subsite I. Discovery of the extended binding area will guide further in-
hibitor development. 
INTRODUCTION 
New classes of antibiotics acting via novel mechanisms are urgently needed to combat 
increasing antibiotic resistance.1-4 A rich source of potential new antibiotic targets is the 
bacterial DNA replisome.5 During bacterial DNA replication and repair, the β-sliding 
clamp subunit (SC) of the DNA polymerase III (Pol III) holoenzyme, a ring-shaped ho-
modimeric protein, encircles DNA and confers high processivity to DNA synthesis (Fig-
ure 1A).6 Components of Pol III that interact with the SC at the same binding site include 
the α polymerase and ε proofreading subunits,7 as well as the clamp loader (γ complex).6 
The variety of SC-focused interactions, the moderate number of SCs per cell (300–600 
dimers),8 the SC’s conserved structure across bacterial species9-11 and its structural diver-
gence from the equivalent human protein (proliferating cell nuclear antigen, PCNA) 12, 13 
make it an attractive target for antibiotic development.5, 14 
Proteins that bind to the SC use short linear motifs (LMs, consensus sequence 
QLx1Lx2F/L: S/D preferred at x1, x2 may be absent)
15, 16 to interact with a LM-binding 
pocket consisting of two subsites (I and II),17, 18 both of which are conserved across 
Gram-negative and Gram-positive species.10 The two N-terminal residues of LMs bind in 
subsite II, while the two or three C-terminal residues occupy subsite I, with the linking 
residues filling a shallow channel between the sites. The side chain of SC residue M362 
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acts as a gate, transitioning from a “closed” (Figure 1B) to an “open” conformation (Fig-
ure 1C–E) upon binding of LM peptides. 
We used structural, biochemical and computational techniques to identify that the inter-
action between LMs and the E. coli SC act via an ‘anchor-based’ sequential binding 
mechanism (Figure 1B–E).19 Des-amino-Leu-Phe (dLF) was identified as a minimal SC-
binding motif that occupies subsite I while maintaining M362 in the “closed” confor-
mation (Figure 1B). In contrast, binding of AcLF stabilizes the "open" conformation of 
M362, accompanied by formation of a hydrogen bond between the acetylated N-terminal 
amide NH of the dipeptide and the carbonyl oxygen of G174 (Figure 1C). Binding of 
AcALDLF to the SC showed electron density for the three C-terminal residues only, 
which occupied subsite I and the channel while holding M362 in the “open” confor-
mation (Figure 1D). Other pentapeptides, including AcQADLF (Figure 1E), were found 
to occupy subsite I, the channel and subsite II. We proposed that this series of peptide-
bound SC structures captured the order of endogenous LM binding events: i.e., binding 
of dLF in subsite I mimics the primary binding contact, AcLF demonstrates subsequent 
formation of the H-bond to G174 with the M362 gate stabilized in the "open" confor-
mation, and AcQADLF demonstrates binding of the N-terminal residues to subsite II by 
forming a network of hydrogen bonds to the glutamine side-chain amide. 
According to the model, subsite I is the first point of contact between LM peptides and 
the SC, acting as the ‘anchor site’ for inhibitor binding. Two classes of non-peptidic 
small-molecule inhibitors, a thioxothiazolinine derivative20 and a biphenyloxime ether21 
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have previously been shown to occupy subsite I (Supporting Information, Figure S1). 
Our recent fragment-based discovery efforts identified several new hits that also bind in 
subsite I.22 Herein we report the design, synthesis, biochemical, biophysical and structur-
al characterization of tetrahydrocarbazole (THC)-based inhibitors that mimic the ‘anchor-
based’ sequential binding of LMs to the E. coli SC. 
 
Figure 1. The sequential binding mechanism of LMs to the SC. (A) The E. coli SC struc-
tures in complex with pentapeptide AcQADLF (PDB entry 4K3O),19 the SC binding-
domain of Pol IV (1UNN)18 and dsDNA (3BEP).17 (B–E) X-ray co-crystal structures 
showing the binding of dLF, AcLF, AcALDLF (the AcAL–portion is disordered) and 
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AcQADLF to the SC binding pocket (PDB entries 4K3K, 4K3L, 4K3M and 4K3O, re-
spectively).19 Dashed lines in red represent H-bonds/salt bridges. A bridging water mole-
cule is shown as a red sphere. Electrostatic potential surfaces in (A) are shown semi-
transparent with blue = positive and red = negative. 
RESULTS 
A Tetrahydrocarbazole Lead Binds to Subsite I as a Mimic of the Anchor Motif. In 
previous work, we showed that the R-enantiomer of racemic tetrahydrocarbazole (THC) 
1 (Figure 2) binds to subsite I of the E. coli SC.22 Here, we explored optimization of THC 
binding to subsite I through substitution of the chlorine atom of 1 by other halogens and 
by shifting the carboxyl group to the 2-position of the cyclohexenyl ring (compounds 1a–
j, Figure 2). Our previously reported fluorescence polarization (FP)-based competition 
assay employing tracer peptide 5-carboxyfluorescein-QLDLF20, 23, 24 was used to quantify 
binding of 1a–j to the E. coli SC.19 Inhibition of tracer binding was plotted against inhibi-
tor concentration to generate IC50 values (Table 1 and Supporting Information, Figure 
S2), which were subsequently transformed into inhibition constants (Ki) using the Ke-
nakin correction for ligand depletion (Table 1).25 Ligand lipophilicity efficiency 
(LLEAT)
26 values were also calculated to inform inhibitor design, with LLEAT values 
around 0.4 targeted (Table 1). 
Racemic 1a was obtained using standard Fisher indole chemistry from commercially 
available 4-chlorophenyl-hydrazine and (±)-3-oxocyclohexanecarboxylic acid (Figure 2). 
1a showed a Ki of 166 µM (Table 1). Esterification of 1a (MeOH, H2SO4 (cat.)) provided 
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1b, while coupling of 1a with ammonium hydroxide in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and N-hydroxy-succinimide (NHS) afforded 
amide 1c. LiAlH4 reduction of 1a gave alcohol 1d.
27, 28 However, none of 1b–d was ac-
tive (Table 1). The stereochemically pure R and S enantiomers of 1a (i.e., 1e and 1f, re-
spectively) were prepared using enantiomerically pure cyclohexane-3-carboxylic acids. 
Fluorinated (1g), iodinated (1h) and brominated analogues (1i and 1j) were obtained with 
the appropriate 4-halophenylhydrazines and chiral cyclohexane-3-carboxylic acids. SC 
inhibition by 1e–j indicated a preference for the R-enantiomer and chloro/bromo/iodo de-
rivatives (Table 1). 
Binding of racemic 1a to the E. coli SC was examined using X-ray crystallography (see 
crystallographic data in Supporting Information, Table S1). Soaking 1a into an apo-SC 
crystal resulted in only the R-enantiomer 1e being observed in the electron density of the 
SC1e complex (Figure 3), consistent with its higher SC affinity relative to 1f (Table 1). 1e 
was found to bind in subsite I of one chain (A) of the SC; the asymmetric unit contained 
a homodimer, chains A and B. Binding of 1e to subsite I of chain B was also observed but 
a nearby crystal contact led us to consider the observed binding of 1e to chain B to be 
less relevant (Supporting Information, Figure S3).  
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Figure 2. THCs (±)-1 and 1a-j. Reagents and conditions: (a) AcOH, reflux, (b) MeOH, 
H2SO4 (cat.), reflux, (c) (i) EDC/NHS, CH2Cl2, rt,( ii) NH4OH, THF, (d) LiAlH4, THF. 
Table 1. Inhibition of the E. coli SC by 1a–j  
 
IC50 
(µM) 
Ki 
(µM) 
cLogD  
(pH 7.2) 
LLEAT 
1a 299 166 0.51 0.38 
1b >1000 – – – 
1c >1000 – – – 
1d >1000 – – – 
1e 134 74 0.51 0.40 
1f 442 246 0.51 0.36 
1g 817 454 –0.11 0.39 
1h 175 97 1.45 0.32 
1i 157 87 0.83 0.37 
1j 328 182 0.83 0.35 
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Binding of 1e positioned the Cl-substituent deep within a hydrophobic pocket of the SC 
comprised of V247, V360, L177 and M362; the same region is occupied by the isobutyr-
yl group of dLF (Figure 1B). The cyclohexenyl ring was observed to bind in the same 
shallow region (containing P242, T172 and L155) occupied by the Phe side chain of dLF. 
A significant difference between the two complexes was that the M362 gate remained 
“closed” (χ2 = –173°, as observed in chain A of the equivalent apo-structure: PDB entry 
1MMI29) upon binding of dLF (Figure 1B), whereas binding of 1e stabilizes the "open" 
conformation of the M362 gate (χ2 = –69°, Figure 3). The "open" conformation of M362 
side-chain was previously identified during molecular dynamics simulation of the apo-
SC crystal structure, but was only maintained as such when peptide ligands were 
bound.19, 24   
Such The carboxylate group of 1e made an H-bond interaction with the phenolic-OH of 
Y154 and a salt-bridge to the R152 guanidinium group. These additional interactions pre-
sumably contributed to the increased SC affinity of 1e (Ki = 74 µM) relative to dLF (Ki > 
1 mM).19 Importantly, the NH group of 1e projected towards the open M362 gate and as-
sociated channel, suggesting a synthetically tractable opportunity (i.e., via N-substitution) 
for directing additional functionality in the direction of subsite II and creating higher po-
tency inhibitors that mimic the endogenous LM binding mechanism. 
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Figure 3. X-ray co-crystal structure of 1e bound to subsite I of the E. coli SC (complex 
designated SC1e). Carbon atoms of the SC and 1e are shown in orange and non-carbon 
atoms are colored according to CPK convention. The apo-SC structure (PDB entry 
1MMI, chain A, shown in yellow) is superimposed onto SC1e for comparison. Pairs of 
atoms are indicated with dashed red lines. The electron density maps (2mFo–DFc) con-
toured at 1σ are shown in blue wire-basket form. 
Inhibitors that Mimic the ‘Anchor-Based’ Sequential Mechanism of LM Binding 
to the E. coli SC. Visual inspection of the SC1e structure (Figure 3) suggested that addi-
tion of an acetamide group to the THC nitrogen of 1e would position the appended amide 
NH in a region where it could potentially make an H-bond to the carbonyl oxygen of 
G174 – directly analogous to the H-bond observed in LM-SC complexes (Figure 1C–E). 
Enantiomeric N-acetamido-THCs 2a and 2b (carrying Cl-substituents) and the corre-
sponding bromo-enantiomers 4a and 4b were synthesized as a test of this hypothesis. 2a 
and 2b were obtained in low yields (4–6%) via a 3-step procedure that involved conver-
sion of acids 1e and 1f to ethyl esters (1k and 1l respectively, Figure 4), N-alkylation of 
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the protected THCs with Cs2CO3/ ICH2CONH2 and final ester hydrolysis. The low alkyl-
ation yields with iodoacetamide led us to pursue an alternative sequence towards the 
bromo analogs 4a and 4b. Carboxylic acids 1i and 1j were first converted to their respec-
tive ethyl esters 1m and 1n and then N-alkylated with tert-butyl bromoacetate in the 
presence of Cs2CO3 in DMF. Removal of the tert-butyl group using neat TFA followed 
by EDC/NHS-mediated amidation with aqueous ammonia and final ethyl ester deprotec-
tion yielded 4a and 4b in 12% and 17% yields, respectively, over 4 steps. 
Compounds 2a and 4a showed higher affinity for the SC than their enantiomeric coun-
terparts 2b and 4b, again reflecting the preference for R-stereochemistry at the ring car-
boxylic acid (Table 2). The co-crystal structure of the SC with 2a (Figure 5A, complex 
denoted SC2a; see crystallographic data in Supporting Information, Table S2) showed that 
the binding pose of 2a is similar to 1e (Figure 3). The conformational changes in the side 
chains of S346 and M362 upon binding of 1e were also observed with 2a and, crucially, 
it was found that the amide-NH of 2a formed the expected H-bond to the carbonyl oxy-
gen of G174. Additionally, as observed with the similarly sized dipeptide AcLF (Figure 
1C), formation of this H-bond coincided with opening of the M362 gate, in agreement 
with our anchor-based sequential binding model.19 The binding mode of 2a suggested 
that further potency increases might be achieved with N-substituted acetamides, which 
could similarly trigger opening of the M362 gate and formation of the H-bond to G174 
while simultaneously projecting additional functionality across the channel towards sub-
site II to mimic the SC-binding mechanism of LMs. 
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Figure 4. Synthesis of N-acetamido-THCs. Reagents and conditions: (a) EtOH, H2SO4 
(cat.), reflux; (b) (i) ICH2CONH2, Cs2CO3, DMF, 80°C, (ii) NaOH, EtOH, rt; (c) (i) tert-
butyl bromoacetate, Cs2CO3, DMF, 80°C, (ii) TFA; (d) (i) EDC/NHS, CH2Cl2, rt, (ii) 
NH4OH(aq), THF, (iii) LiOH, THF, rt; (e) (i) NH2-R2, HATU, DIPEA, DMF, rt, (ii) NaOH 
or LiOH, EtOH, rt; (f) neat TFA. 
Table 2. Inhibition of the E. coli SC by N-Acetamido-THCs 
 
IC50 
(µM) 
Ki 
(µM) 
LogD 
(pH 
7.2) 
LLEA
T 
2a 368 204 –0.75 0.40 
2b 888 493 –0.75 0.38 
4a 246 137 –0.73 0.41 
4b 285 158 –0.73 0.41 
5a 85 47 –4.76 0.61 
N
H
X R
1
a
N
H
X R
1
R1 =X = Cl (R)-CO2Et 1k
(S)-CO2Et 1l
(R)-CO2Et
(S)-CO2Et
1m
1n
1e,1f,1i,1j
(R)-CO2H 2a
(S)-CO2H 2b
NCl
R1
b
R1 =
O
NH2
N
X R
1
c
d
Br
Br
Cl
O
OH
NBr
R1
O
NH2
X = (R)-CO2Et
(S)-CO2Et
3a
3bBr
Br (R)-CO2H 4a
(S)-CO2H 4b
R1 =
Cl (R)-CO2Et 3c
e
N
X CO2H
H
N
O
R2
X R2
Cl 5a
Br 5b
Cl 5c
CH2CO2H
CH2CO2H
CH2CH3
N BocH2C
5dCl
5eBr
NHH2C 5fBr
Br 5gCH2CONH2
O
NH2
H2C 5h
Br
N 5iBr
O
NH2
(D)-Lys(Boc)-OH 5jBr
(L)-Leu-OH 5kBr
(D)-Phe-OH 5lBr
(L)-Phe-OH 5mBr
5a-e, g-m
5e
R
5f
f
R1 =
O
NH2
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5b 20 11 –4.63 0.64 
5c 347 193 0.01 0.33 
5d 362 201 0.20 0.27 
5e 150 83 1.23 0.22 
5f 208 116 –1.00 0.35 
5g 171 95 –1.79 0.43 
5h 64 36 0.18 0.30 
5i 307 171 0.27 0.27 
5j 115 64 –3.26 0.40 
5k 48 27 –3.57 0.50 
5l 30 17 –3.19 0.45 
5m 27 15 –3.19 0.45 
Aspartate or glutamate residues are often present in SC-binding LMs, serving as bridg-
ing residues that occupy the channel region between subsites I and II (Figure 1D–E). 15, 19, 
24 We predicted that glycinamides 5a and 5b (Figure 4) would position their Gly carbox-
ylate groups into the region occupied by LM Asp and Glu side chains. To test this, 5a and 
5b were prepared in modest yields (10–40%) from their precursor ethyl esters 3a and 3c 
by first coupling glycine methyl ester using standard amide coupling conditions (HATU, 
DIPEA, DMF) and then simultaneously hydrolyzing the methyl and ethyl esters with 
base. The precursor ester 3c was prepared as for 3a from 4-chlorophenylhydrazine in 
Page 12 of 36
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 13
59% yield over 4 steps (Figure 4). 5a and 5b both contained R-configured carboxylates at 
the 2-position. The S-enantiomers of 5a and 5b (and other inhibitors) were not investi-
gated beyond this point due to the lower SC affinity observed (Tables 1 and 2). The bro-
mo-acid analog 5b showed higher potency (Ki = 11 µM, Table 2) relative to the corre-
sponding primary amide 4a (Ki = 137 µM) and the chloro-analog 5a (Ki = 47 µM). These 
results led us to focus subsequent efforts on bromo-THCs. 
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Figure 5. X-ray co-crystal structure of (A) 2a, (B) 5b and (C) 5l bound to the E. coli 
SC (complexes designated SC2a, SC5b and SC5l, respectively). The complexes are repre-
sented with carbon atoms shown in orange and non-carbon atoms following CPK con-
vention. The apo-SC structure (PDB entry 1MMI, chain A, shown in lemon) is superim-
posed on each complex for comparison. Inhibitor electron density maps (2mFo–DFc) 
contoured at 1σ are shown in blue wire-basket form. 
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A co-crystal structure of the SC with 5b (Figure 5B, complex denoted SC5b; see crystal-
lographic data in Supporting Information, Table S1) showed that 5b made all of the same 
SC interactions as 2a (Figure 5A). The appended glycine carboxylate of 5b, however, 
made additional hydrogen bond/salt bridge contacts with the side chains of R152 and 
H175, thus explaining its higher potency relative to its parent amide 4a. As expected, the 
glycyl group occupied the channel region between subsites I and II, mimicking the chan-
nel-binding Asp residues in LMs (Figure 1D, E). 5c–i (Figure 4), synthesized in variable 
yields (4–64%) using similar methods, were found to have reduced potency relative to 5b 
(Table 2). Amino acid-containing compounds 5j–m were examined next to explore 
whether side chains appended to the 5b glycine α-carbon could occupy subsite II. 5l and 
5m were prepared in moderate yields (30–57%) via amide coupling reactions of D- and 
L-phenylalanine methyl esters with 3a, respectively, followed by global methyl/ethyl es-
ter deprotection using base (Figure 4). Both 5l and 5m (Ki = 17 and 15 µM, respectively, 
Table 2) showed similar SC affinities to 5b (Ki = 11 µM, Table 2).  
A co-crystal structure of the SC with 5l (Figure 5C, complex denoted SC5l; crystallo-
graphic data in Supporting Information, Table S1) showed that the overall binding pose 
of 5l was similar to that of 5b (Figure 5B). 5l extended to the edge of subsite II where its 
phenyl ring occupied part of the space filled by LM peptide sub-motifs (Figure 1E). The 
M362 side chain adopted alternate conformations upon binding of 5l, one where it dis-
played the usual “open” state whilst in the other it was shifted towards subsite II due to 
an interaction with the phenyl ring. 
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The binding of inhibitors 1e, 2a, 5b and 5l to the E. coli SC closely matched our ‘an-
chor’-based LM sequential binding mechanism.19 Compound 1e is positioned as an ‘an-
chor’ in subsite I. Having the same THC moiety anchored in subsite I, compounds 2a, 5b 
and 5l  maintained the M362 gate in the open conformation and made the H-bond inter-
action with G174– features uniformly observed in LM-bound SC structures. It therefore 
seems likely that binding of 2a, 5b and 5l (and probably other THC-based inhibitors) 
would invoke the sequential binding mechanisms of LMs; i.e., where the THC group 
makes initial contact with subsite I, captures the "open" state of the M362 gate and then 
redirection of the appended groups occurs leading to formation of the G174 H-bond. This 
assertion is supported by the poses adopted by 2a and 5l when bound to the SC chain B 
(Supporting Information, Figure S3). Inhibitor binding to chain B beyond subsite I is im-
peded by the presence of the SC symmetry partner – a crystallographic artefact. In these 
structures, 2a and 5l positioned their THC moieties in subsite I but their appended groups 
were shunted away from the channel and subsite II into solvent by the crystallographic 
symmetry partner. 
Ligand-Induced Loop Rearrangement Creates an Additional Binding Pocket. The 
observation of similar SC binding affinities for diastereomers 5l and 5m (containing D- 
or L-Phe moieties, respectively) led us to investigate the binding pose adopted by 5m. 
SC/5m co-crystal structures were solved (denoted SC5m, Figure 6A; crystallographic data 
in Supporting Information, Table S2) and the apo-SC structure with similar cell dimen-
sions was also solved for comparison (denoted SCapo; crystallographic data in Supporting 
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Information, Table S2). 5m was observed to bind to chain B of this SC crystal with its 
THC unit occupying subsite I, as observed with other THCs. The symmetry partners that 
had occupied the channel region and subsite II of chain B in other SC crystals of smaller 
cell dimensions were not observed with this structure. The binding of 5m caused similar 
conformation changes in the side chains of S346 and M362 to those observed in other 
THC-SC structures; however, a dramatic rearrangement in the loop region comprising 
H148–Y154 was induced upon binding of 5m (Figure 6A; additional electron density 
maps highlighting the differences between the loop regions of SCapo and SC5m are pro-
vided in Supporting Information, Figure S4). While the H148 and Y154 residues at the 
start and end of the loop had undergone minor changes in their side chain conformations, 
the residue pair of Q149 and D150 had exchanged positions. The residue pair of R152 
and Y153 had also exchanged positions and V151, located in the middle of the loop, had 
moved to accommodate these changes. 
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Figure 6. Co-crystal structure of 5m bound to the E. coli SC. (A) SC5m is displayed with 
carbon atoms in orange and non-carbon atoms colored according to CPK convention. The 
SCapo structure is superimposed onto SC5m for comparison (carbon atoms colored yellow 
and non-carbon atoms in CPK colors). Hydrogen bonds are indicated with dashed red 
lines. Purple and green arrows indicate movement of SC residues in the SCapo vs. SC5m 
structure. Electron density maps (2mFo–DFc) contoured at 1σ are shown in blue wire-
basket form. (B and C) Electrostatic potential surfaces of the binding sites in SCapo and 
SC5m shown in semi-transparent form (blue = positive; red = negative). (D and (E) Struc-
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tural overlap of SC5m and dsDNA-bound SC (PDB entry 3BEP) with carbon atoms in or-
ange and cyan respectively. Atoms of DNA molecules are in CPK colors and the nucleic 
acid bases are also represented as blocks (A: red, G: green, T: yellow, C: blue). The dsD-
NA axis is directed at the viewer in (D) and the system is rotated 90° clockwise in (E). 
The loop rearrangement significantly altered the surface geometry and electrostatics in 
this region of the SC (Figures 6B and C). The charged area originally occupied by the 
side chains of R152 and D150 and the surrounding residues G174, Y154 and H175 in 
SCapo were replaced by neutral residues Y153 and Q149 in SC5m to accommodate the hy-
drophobic phenyl ring of 5m. We denote the new ligand-induced binding area, compris-
ing G174, Y154, Y153, Q149 and H175 as “subsite III”. It is of note that the phenyl 
group of 5m occupied only half of subsite III, leaving the area between H175 and Q149 
vacant and potentially available for further targeting.  
Sequence alignments comparing the LM binding pockets and H148–Y154 loop regions 
of SCs from representative Gram-negative (E. coli, Acinetobacter baylyi, A. baumannii 
and Pseudomonas aeruginosa) and Gram-positive (Staphylococcus aureus, Bacillus sub-
tilis, Streptococcus pneumoniae and S. pyogenes) species (Supporting Information, Fig-
ure S5) show that the switching residue pairs in the loop region (i.e., Q149–D150 and 
R152–Y153), along with V151, are well conserved across the Gram-negatives, but less 
so among the Gram-positives. This suggests that the ligand-induced loop rearrangement 
may be a feature common to Gram-negative species. The conformational change is also 
of interest because the rearranged loop is located at the inner edge of the SC dimer in the 
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region through which dsDNA passes (Figure 4D, E). The ~10 Å movement of V151 to-
wards the center of the ring positioned it where dsDNA would be expected to bind (see 
PDB entry 3BEP).17 The movements in several residues involved in both the binding of 
5m and ssDNA/dsDNA shows that this region is open to remodeling by ligands.In addi-
tion to inhibiting LM binding, 5m may also act as an inhibitor of the SC/DNA interac-
tion. This hypothesis may in part be corroborated by the E. coli SC-DNA complex crystal 
structure, 17 which demonstrated side-chain movement of Q149 upon dsDNA binding due 
to steric hindrance, and residues Y153 and Y154 interacting with a nearby ssDNA seg-
ment from a symmetry-related molecule. 
Dissociation Constants of Complexes of THC Derivatives with the E. coli SC. 
Thermodynamic data for the binding of THCs 5a, 5b, 5l and 5m to the E. coli SC were 
obtained using isothermal titration calorimetry (ITC). In all cases the observed dissocia-
tion constants, Kd (Table 3 and Supporting Information Figure S6) matched well the Ki 
values obtained from the fluorescence polarization assays (Table 2; Supplementary In-
formation, Figure S2). The thermodynamic profiles (∆H and –T∆S values) for each inhib-
itor were also similar, consistent with their closely related binding poses in subsite I. In-
terestingly, the loop rearrangement induced in the SC upon binding of 5m did not signifi-
cantly alter the enthalpy or entropy of binding relative to other inhibitors. 
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Table 3. ITC Data (298 K) for the Binding of THC Derivatives to the E. coli SC 
 
∆H 
(kcal/mol) 
–T∆S 
(kcal/mol) 
∆G 
(kcal/mol) 
Kd (µM) 
5a –13.2 ± 0.16 6.8 –6.3 24 ± 2 
5b –15.1 ± 0.12 8.5 –6.6 14 ± 0.9 
5l –12.0 ± 0.1 5.3 –6.6 13 ± 1 
5m –13.7 ± 0.13 6.8 –6.9 9 ± 0.8 
THC Derivatives Inhibit in vitro DNA Replication. DNA replication assays were 
used to demonstrate inhibition of E. coli SC function by THC derivatives 1e, 1i, 2a, 4a, 
5a, 5b, 5l and 5m. Briefly, circular ssDNA with an RNA primer was used as template in 
a minimized reaction system containing the SC, single-stranded DNA-binding protein 
(SSB), the Pol III α subunit and the reconstituted γ3δδ' clamp loader complex.
30 In this 
system purposely minimized to avoid potentially confounding effects of inhibitors on 
other protein–protein interactions in more efficient full-replisome systems,{Jergic, 2013 
#238} the SC is loaded onto the primed DNA by the clamp loader complex, which is 
subsequently released.17, 31, 32 Binding of the α subunit leads to extension of the primer 
through incorporation of dNTPs using the primed ssDNA as template33, 34 (see Support-
ing Information, Figures S7 and S8 for a schematic representation of the assay and a con-
trol experiment). Binding of the DNA Pol III δ and α subunits to the SC is essential for 
DNA replication to occur in this system and is impaired by the presence of inhibitors. In-
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hibition of SC binding leaves residual ssDNA templates and incomplete dsDNA prod-
ucts, whereas successful synthesis yields complete dsDNA products (Figure 7). 
 
Figure 7. Inhibition of E. coli SC-mediated in vitro DNA replication by 1e, 1i, 2a, 4a, 
5a, 5b, 5l and 5m. DNA laddersindicate 8, 6, 5, 4 and 3 kilobase pairs of DNA in each 
panel (top to bottom). Ladder = DNA molecular size standards. Circles with a short line 
above represent RNA-primed ssDNA templates. Two concentric circles represent 
completed dsDNA synthesis products.  
Compounds 1e, 1i, 2a and 4a inhibited DNA replication at concentrations >125 µM 
(Figure 7), consistent with their relatively weak SC affinities (Ki = 74–204 µM, Tables 1 
and 2). Compounds 5a (Ki = 47 µM) inhibited DNA replication at concentrations >63 
µM, while 5b (Ki = 11 µM), 5l (Ki = 17 µM) and 5m (Ki = 15 µM) all showed inhibitory 
effects at 31 µM, consistent with their higher SC affinities.  
DISCUSSION 
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A characteristic feature of linear motif (LM) recognition by the E. coli sliding clamp 
(SC) is separation of the LM binding pocket on the SC surface into two distinct subsites 
(subsites I and II), with an intervening channel region gated by the side chain of M362. 
Subsite I acts as the anchor site for binding of ‘anchor motifs’ in the consensus sequences 
of partner proteins.19 All SC inhibitors identified to date bind in subsite I. Our sequential 
binding model19 describes how binding events at the channel region and subsite II occur 
only after ligands are first ‘anchored’ into subsite I. Tetrahydrocarbazole (THC) deriva-
tives 1e and 1i were identified as ligands that act as anchor moieties in subsite I, while at 
the same time positioning their THC nitrogen in an orientation that allowed additional 
functionality to be added and projected into the channel towards subsite II, thus matching 
the binding mechanism of LM consensus peptide ligands. The hydrogen bond with G174 
and the “open” conformation of the M362 gating residue, which are both consistently ob-
served upon LM peptide binding, were reproduced by members of the N-linked THCs, 
exemplified by 2a, 5b and 5l (Figure 5). Compound 5l was found to occupy subsite I, the 
channel region and the edge of subsite II, providing valuable insights for future work to, 
for example, extend inhibitors farther into subsite II by substituting the phenyl ring of the 
D-phenylalanine moiety or by replacing it with other functionalized D-amino acids. 
The binding of 5m to the E. coli SC induced a loop rearrangement that resulted in posi-
tional switching of residue pairs Q149–D150 and R152–Y153 and a 10 Å movement of 
V151. To our knowledge, no peptides or synthetic entities that bind the SC (including the 
clamp-loader complex, which can pry open the SC dimer ring)17 have been observed to 
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exert such allosteric effect. This ligand-induced rearrangement revealed a hitherto unre-
ported binding pocket, which we denote ‘subsite III’. Compound 5m did not form the 
hydrogen bond with G174 observed with other THC derivatives (Figure 6A), nor did its 
carboxylate group make interactions with R152 and H175 (as observed with 5b and 5l; 
Figure 5B and C). Nonetheless, 5m displayed similar SC affinity to 5b and 5l, suggesting 
that the SC conformational changes and occupancy of subsite III by 5m contributed fa-
vorably to binding (Figure 6C). Subsite III therefore appears as an attractive ‘ligand-
induced’ site for targeting through further substitution of 5m or related structures. Com-
pounds of this type have potential to inhibit the SCs of Gram-negative bacteria in particu-
lar, due to their well conserved subsite I and loop residues H149–Y153. The possibility 
that 5m and associated derivatives might also modulate SC–DNA interactions is intri-
guing but remains to be investigated. 
THC derivatives 5b, 5l and 5m showed >10-fold increases in SC affinity relative to ini-
tial hit 1a, and also have increased LLEAT values. The previously described thioxothia-
zolinine derivative and biphenyloxime derivative SC inhibitors (Supporting Information, 
Figure S1) bound to subsite I and showed affinities >10 µM.  THC derivatives 5l and 5m 
displayed similar SC affinities achieved through expanded binding site coverage to com-
pensate reduced ligand efficiency, with 5l extending to the edge of subsite II and 5m re-
vealing the new subsite III. Both compounds provide synthetically accessible possibili-
ties for evolving further generations of inhibitors that fully occupy subsites I and II or III 
and show increased potency.  
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Binding of these N-substituted THCs was in good agreement with the anchor-based se-
quential binding mechanism proposed for SC-binding LM peptides.19 The substituted 
THC anchor motifs occupied subsite I first, followed by positioning of the rest of the lig-
and. This observation may be generally applicable for development of inhibitors of LM 
binding, since other LMs may also possess key ‘anchor’ residues that drive binding to 
partner proteins.35, 36 Similar inhibitor design strategies may be successful when applied 
in evolutionarily related and/or biochemically similar systems. For example, the eukary-
otic SC homolog, PCNA, that mediates interactions in eukaryotic DNA replication via 
recognition of a Qxx[I/L]xxFF motif,12 has been suggested as an anticancer target.37 Tar-
geting ‘anchor sites’ and adjacent areas in this (and other) systems, after delineating the 
mechanisms of LM recognition, may serve as an effective strategy for inhibitor design. 
MATERIALS AND METHODS 
Chemo-informatics, Bioinformatics and Organic Synthesis. Compounds were ≥ 
95% pure as confirmed by 1H NMR. Full details are given in the Supporting Information. 
Protein Expression and Purification. Expression and purification of the E. coli SC, 
Pol III α subunit, SSB and the γ3δδ’ clamp loader complex were as described previously. 
16, 30, 38 
Crystallization and X-Ray Data Collection. Crystals of the E. coli SC were grown at 
285 K by the hanging-drop vapor diffusion method. The hanging drop was composed of 
1 µl of sliding clamp (53 mg/mL in 10 mM Tris-HCl pH 7.2, 1 mM dithiothreitol, 1 mM 
EDTA and 15% glycerol) mixed with an equal volume of reservoir solution consisting of 
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100 mM MES pH 6.5, 100–150 mM CaCl2 and 25–30% (v/v) PEG400. The reservoir 
volume was 1 mL. SC crystals were transferred to a CaCl2-free reservoir and ligands 
were soaked into the crystal at 2–5 mM in reservoir solution with <10% DMSO. All crys-
tals were mounted using MiTeGen loops on pins with magnetic caps. For in-house data 
collection, crystals were flash-frozen at 100 K using an Oxford Cryo-stream. Diffraction 
data were collected using a Mar345 desktop beamline using CuKα X-rays from a Rigaku 
007HF rotating anode generator with Varimax optics. For synchrotron data collection, the 
SSRL automated mounting system (SAM) was used. Mounted crystals were flash-frozen 
in liquid nitrogen and placed in the SAM cassettes. Diffraction data were collected at 100 
K at the Australian Synchrotron, Beamline MX1 using X-rays of wavelength 0.95 Å. 
Data Processing, Structure Solution and Refinement. Crystal data sets were inte-
grated, merged and scaled with HKL200039 or MOSFLM and SCALA.40 The structures 
were solved by molecular replacement with CCP4 using the Protein Data Bank entry 
1MMI29 or 4K3S19 as the starting model. Iterative cycles of model building and refine-
ment were performed in COOT41 and REFMAC5. 42 
Fluorescence Polarization Assay. Experiments and data processing protocols were re-
ported previously.19 All FP experiments were conducted using a POLARstar Omega plate 
reader with non-treated black sterile 96-well plates (Greiner, USA). The buffer contained 
10 mM HEPES pH 7.4, 1 mM EDTA, 1 mM dithiothreitol, 0.07% Nonidet P-40 and 5% 
DMSO. The fluorescent tracer used was N-fluorescein (FAM)-QLDLF-OH (GL Bio-
chem, China), which has a Kd of 70 nM for SC monomers. For the competition assay, 10 
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nM peptide and 50 nM sliding clamp (as monomers) were used. Blank control (buffer), 
negative control (buffer and the peptide) and positive control (buffer, peptide and the 
sliding clamp) were used for data normalization. Data are shown as % inhibition relative 
to maximum, calculated as the decrease in polarization from maximum divided by the 
background-subtracted total polarization. Experiments were carried out in duplicate. 
Curves were fit using GraphPad Prism v5.01 (GraphPad Software, USA) and data are 
presented as "best-fit" values. Dose-response curve fitting was applied to competition as-
says with variable slope.  
Isothermal Titration Calorimetry. ITC used a MicroCal Auto-iTC200 calorimeter 
(GE Healthcare) at 298 K. The SC was dialyzed against a buffer (10 mM HEPES pH 7.2, 
0.15 M NaCl and 1 mM EDTA) and the same buffer was used to dissolve the com-
pounds. The feedback mode was “high” with a reference power setting of 10 µcal/s. The 
cell was stirred at 1000 rpm and the thermostat set at 25 °C. Experiments were conducted 
with 19 injections of 2 µL over 4s with 200s intervals between injections. The first injec-
tion (of 0.4 µL) was discarded in all cases. Compounds (0.7-1 mM) were titrated in se-
quential injections into 75 µM SC monomer. Data were corrected for control experiments 
with compounds titrated into buffer only. Data analysis was carried out with Origin 7.0 
using one-site binding data fitting. 
DNA replication assay. The RNA-primed DNA template was prepared in advance by 
mixing 35 nM wild-type M13 ssDNA26 with 1 µM oligoribonucleotide (5’-
UAUGUACC-CCGGUUGAUAAUCAGAAAAGCCCCA; GeneWorks, Australia) in 30 
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mM Tris-HCl pH 7.6, 15 mM MgCl2, 130 mM NaCl and 0.1 mM EDTA for 10 min at 55 
°C and cooling to room temperature over a period of 8 h. The DNA replication assays 
contained: 20 mM Tris-HCl pH 7.6, 10 mM MgCl2, 0.8 mM ATP, 8.4 mM dithiothreitol, 
0.6 mM of each dNTP, 50 nM Pol III α subunit, 700 nM SSB (as tetramers), 210 nM Pol 
III β sliding clamp (as dimers), 42 nM γ3δδ’ clamp loader complex, 120 mM NaCl and 3 
nM RNA primed DNA template, in a volume of 15 µL. Inhibitors (peptides or THC de-
rivatives) were dissolved in DMSO and diluted in series 2-fold (in 50% v/v DMSO) be-
fore being added (0.5 µL) to the assay mixture at 0°C. The final DMSO concentration 
was 3.4% (v/v) in all assays. The assay mixtures were treated at 30 °C for 60 min before 
being quenched by the addition of EDTA to 150 mM and SDS to 1% (w/v). The DNA 
products were separated by 0.7% agarose gel electrophoresis in TAE buffer (80 mM Tris, 
40 mM acetic acid, and 4 mM EDTA) and then stained with 10,000-fold diluted SYBR 
Gold (Life Technologies) for 60 min. The DNA products were visualized using a UV 
transilluminator. 
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The atomic coordinates and structure factors for SC1e, SC2a, SC5b, SC5l, SCapo and SC5m 
have been deposited in the Protein Data Bank with accession codes 4OVF, 4OVG, 
4OVH, 4PNU, 4PNV and 4PNW, respectively.  
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dNTP, deoxyribonucleoside triphosphate; dsDNA, double-stranded DNA; dLF, des-
amino-Leu-Phe; DMF, dimethylformamide; DIPEA, N,N-diisopropylethylamine; EDC, 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide;  FP, fluorescence polarization; HATU, 
N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-
methylmethanaminium hexafluorophosphate N-oxide; IC50, half-maximum inhibitory 
concentration; Ki, inhibition constant; LogD, distribution coefficient; LE, ligand efficien-
cy; LLEAT, ligand lipophilicity efficiency; LM, linear motif; NHS, N-
hydroxysuccinimide; PCNA, proliferating cell nuclear antigen; PDB, protein data bank; 
Pol, polymerase; SC, sliding clamp; ssDNA, single-stranded DNA;  TFA, trifluoroacetic 
acid; THC, tetrahydrocarbazole. 
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Supplementary Results 
 
 
Figure S1. X-ray co-crystal structures of the E. coli SC in complex with (A) a thioxothiazolinine derivative 
(PDB entry 3D1G)1 and (B) a biphenyloxime ether derivative (PDB entry 3QSB).2 Carbon atoms are colored 
orange and non-carbon atoms follow CPK convention. Both inhibitors occupy subsite I. 
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Figure S2. Dose-response curves of representative THC analogs inhibiting the E. coli SC, as measured by 
fluorescence polarization. 
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Table S1. Data collection and refinement statistics for X-ray co-crystal structures of the E. coli SC in 
complex with compounds 1e, 2a, 5b and 5l 
Name SC1e SC2a SC5b SC5l 
PDB Code 4OVF 4OVG 4OVH 4PNU 
Data collection 
Space group P21 
Cell dimensions 
a, b, c (Å) / α, β, γ (°) 
79.87, 67.26, 81.19 /    
90.00, 114.27, 90.00 
a, b, c (Å) / α, β, γ (°) 
80.08, 66.20, 80.62 /    
90.00, 114.89, 90.00 
a, b, c (Å) / α, β, γ (°) 
80.03, 66.42, 80.79 /    
90.00, 114.76, 90.00 
a, b, c (Å) / α, β, γ (°) 
79.89, 67.19, 81.02 /    
90.00, 114.54, 90.00 
Resolution (Å) 50.00–2.05 (2.12–2.05) 40.00–1.90 (1.97–1.90) 30.00–2.25 (1.79–1.70) 30.00–1.90 (1.97–1.90) 
Rmerge (%) 4.3 (26.1) 2.8 (17.1) 7.1 (45.6) 3.2 (38.0) 
No. of Reflections 169349 219352 116359 217379 
Unique Reflections 49386 (4716) 60330 (6013) 37099 (3029) 61732 (5986) 
Mean I/σ(I) 27.4 (3.5) 41.5 (7.0) 16.6 (2.2) 36.1 (2.7) 
Completeness (%) 96.4 (95.9) 99.9 (100.0) 96.4 (82.4) 99.7 (97.4) 
Multiplicity 3.6 (3.5) 3.7 (3.5) 3.1 (2.6) 3.5 (3.1) 
Refinement 
Resolution (Å) 34.61–2.05 (2.10–2.05) 21.62–1.90 (1.95–1.90) 29.82–2.24 (2.29–2.24) 28.27–1.90 (1.95–1.90) 
Rwork / Rfree (%) 21.0 (19.7) / 27.0 (29.9) 18.0 (21.9) / 22.6 (27.3) 19.2 (20.5) / 25.0 (32.1) 18.2 (25.0) / 23.0 (28.9) 
RMS deviations     
Bond lengths (Å) 0.0056 0.0108 0.0070 0.0071 
Bond angles (º) 1.0960 1.5211 1.2173 1.2654 
B-factors     
main chain 22.6 17.1 24.8 17.8 
sidechain & water 26.4 21.7 26.8 22.1 
ligand* 32.7 22.1 33.1 20.3 
Ramachandran 
Plot Outliers 
0.43% 0.29% 0.42% 0.29% 
 
Values for data in the highest resolution shell are given in parentheses. 
Diffraction data were collected using a Rigaku 007HF X-ray generator producing Cu Kα X-rays (wavelength of 1.5418 Å) and 
Mar345dtb area detector. Diffraction data were processed using HKL2000.3 
*Ligand refers to the compounds bound to SC chain A.
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Figure S3. X-ray co-crystal structures of the E. coli SC showing chain B in complex with compounds 1e, 2a 
and 5l. Carbon atoms of SC chain A/B and the bound compounds 1e, 2a and 5l are colored 
orange/magenta respectively. All other atoms are colored according to the CPK convention. The SC 
symmetry partner is shown in gray. SC chain A is superimposed with chain B in the enlarged views and the 
electrostatic potential surfaces of chain B are shown with blue = positive and red = negative. Electron 
density maps (2mFo–DFc) contoured at 1σ are shown in blue wire-basket form.   
SC Chain A/1e 
SC Chain B/1e 
Symmetry mate 
 
SC Chain A/2a 
SC Chain B/2a 
Symmetry mate 
 
SC Chain A/5l 
SC Chain B/5l 
Symmetry mate 
 
6	  
	  
 
 
Table S2. Data collection and refinement statistics for the X-ray crystal structures of apo-E. coli SC 
(SCapo) and E. coli SC in complex with compound 5m (SC5m), respectively 
Structure Name SCapo SC5m 
PDB Code 4PNV 4PNW 
Data collection 
Space group P21 
Cell dimensions 
a, b, c (Å) / α, β, γ (°) 
80.14, 70.26, 84.47 /    
90.00, 114.67, 90.00 
a, b, c (Å) / α, β, γ (°) 
79.81, 68.71, 83.06 / 
90.00, 115.72, 90.00 
Resolution (Å) 30.00–1.86 (1.93–1.86) 30.00–2.00 (2.07–2.00) 
Rmerge (%) 2.8 (31.9) 5.1 (45.6) 
No. of Reflections 251660 188410 
Unique Reflections 71719 (6779) 55049 (5267) 
Mean I/σ(I) 41.1 (3.2) 24.0 (2.6) 
Completeness (%) 99.3 (95.3) 98.0 (96.2) 
Multiplicity 3.5 (3.1) 3.4 (3.2) 
Refinement 
Resolution (Å) 27.55–1.86 (1.91–1.86) 28.01–2.00 (2.05–2.00) 
Rwork / Rfree (%) 18.3(26.0) / 23.3(33.8) 18.4(20.4) / 23.3(28.2) 
R.M.S. deviations   
Bond lengths (Å) 0.0067 0.0079 
Bond angles (º) 1.2017 1.3198 
B-factors   
mainchain 19.4 23.1 
sidechain & water 23.8 26.8 
ligand* N/a 39.4 
Ramachandran Plot Outliers 0.29% 0.57 % 
 
Values for data in the highest resolution shell are given in parentheses. 
Diffraction data were collected using a Rigaku 007HF X-ray generator producing Cu Kα X-
rays (wavelength of 1.5418 Å) and Mar345dtb area detector. Diffraction data were 
processed with HKL2000.3 
*Ligand refers to compounds bound to SC Chain B.
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Figure S4. Stereo view of the loop rearrangement induced upon binding of compound 5m to the E. coli SC.  
(A) The H148–Y154 loop region of SCapo. Carbon atoms are shown in yellow. All other atoms are colored 
according to CPK convention. (B) The H148–Y154 loop region of SC5m. Carbon atoms are colored orange. 
All other atoms are colored according to CPK convention. Electron density maps (2mFo–DFc) contoured at 
1σ are shown in blue wire-basket form. 
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Figure S5. Sequence Alignment of SCs from four representative Gram-negative (Escherichia coli, Acinetobacter baylyi, Acinetobacter 
baumannii and Pseudomonas aeruginosa) and four Gram-positive bacterial species (Staphylococcus aureus, Bacillus subtilis, 
Streptococcus pneumoniae and Streptococcus pyogenes). Red box indicates the H148–Y154 loop region. The switching pairs of residues, 
i.e., Q149–D150 and R152–Y153, are highlighted in purple and V151 in green for the Gram-negative species. Residues comprising 
subsites I and II are highlighted in yellow. Numbering is based on the E. coli SC sequence. 
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Figure S6. Isothermal titration calorimetry data for the binding of (A) 5a, (B) 5b, (C) 5l and (D) 5m to the E. 
coli SC. 
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Figure S7. Schematic representation of the in vitro DNA replication assay. 
 
 
 
Figure S8. Control in vitro DNA replication assay. Molecular sizes (in bp) corresponding to bands in the 
DNA ladder are shown. The circle with dashed line above represents primed ssDNA template. Two 
concentric circles represent completed dsDNA replication products. 
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Supplementary Methods  
Chemo-informatics. LogD values at pH 7.2 were calculated using Accord for Excel 6.2 (Accelrys). 
Calculations of Ligand Lipophilicity Efficiency (LLEAT) followed the published methods4 and are summarized 
below: 
∆G* = ∆G – ∆Glipo 
        = RTln(Ki) + RTLogD 
LLEAT = 0.11 - ∆G*/HAC 
∆G: difference in Gibbs free energy; Ki: inhibition constant; HAC: heavy atom count; LogD: distribution 
coefficient at pH 7.2. 
Bioinformatics. Sequence alignments of bacterial sliding clamps (NCBI IDs: YP_859300.1, 
WP_004930066.1, ZP_08441263.1, NP_064722.1, NP_373240.1, WP_003242509.1, YP_815419.1 and 
AAF98349.2) were carried out with COBALT.5 
Chemistry – General. 1H and 13C NMR spectra were acquired on a Varian Mercury 300 MHz, Varian Inova 
500 MHz or VNMRS 500 MHz spectrometer. Chemical shifts (δ) are reported in ppm relative to the solvent 
and coupling constants (J) are in Hz. Electrospray ionisation (EI) low resolution mass spectra (LRMS) were 
recorded on a Waters Micromass Platform LCZ spectrometer. High resolution mass spectra (HRMS) were 
recorded on a Waters Xevo spectrometer using either an EI source or atmospheric solids analysis probe 
(ASAP). Melting points were recorded using a Gallenkamp (Griffin) melting point apparatus and are 
uncorrected. Optical rotations were measured on a Jasco P-2000 polarimeter. TLC analysis was performed 
using pre-coated Merck silica gel 60 PF254 aluminium sheets. Flash column chromatography was 
performed using Davisil silica gel (40-63 µm). Petrol refers to petroleum spirits of bp 40–60°C. All 
compounds examined showed ≥ 95% purity by 1H NMR and HPLC-MS. 
 
(±)-6-Chloro-2,3,4,9-tetrahydrocarbazole-2-carboxylic acid (1a).6,7 To a solution of 4-chlorophenyl-
hydrazine hydrochloride (305 mg, 1.70 mmol) in glacial acetic acid (2 mL) was 
added 3-oxo-cyclohexanecarboxylic acid (237 mg, 1.67 mmol) in glacial acetic 
acid (2 mL) and the mixture heated at reflux overnight. The reaction mixture 
was cooled and the resulting precipitate collected by vacuum filtration and 
washed with cold water. The resultant solid was purified by silica gel column 
chromatography (25:75:0.5 to 50:50:0.5 Et2O/petrol/AcOH) followed by recrystallization from EtOH/H2O to 
give 1a (42 mg, 10% yield) as a yellow powder: mp 242–244°C (lit.6 249–250°C); 1H NMR (DMSO-d6, 500 
MHz): δ 1.80–183 (1H, m), 2.14–2.16 (1H, m), 2.56–2.92 (5H, m), 6.97 (1H, d, J = 8.0 Hz), 7.24 (1H, d, J = 
8.5 Hz), 7.34 (1H, s), 10.90 (1H, s), 12.32 (1H, s.); 13C NMR (DMSO-d6, 125 MHz): δ 19.4, 25.1, 25.7, 39.3, 
107.6, 112.0, 116.5, 119.9, 122.8, 128.1, 134.3, 135.2, 175.97; LRMS (ES+) m/z: 272.2 [M+Na]+; HRMS 
(ASAP+) calcd. for C13H13NO2Cl [M+H]+ 250.0635, found 250.0628.  
 
(±)-Methyl 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylate (1b).6 To a solution of 1a (50 mg, 
0.20 mmol) in MeOH (1.5 mL) was added concentrated H2SO4 (200 µL) and 
the mixture heated at reflux overnight. The resulting solution was cooled, 
concentrated to dryness, treated with saturated aqueous NaHCO3 and 
extracted with EtOAc (3 x 10 mL). The combined organic extracts were 
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washed with water (10 mL) and brine (10 mL), dried over anhydrous MgSO4 and concentrated. The crude 
residue was recrystallized from MeOH/H2O to give 1b (16 mg, 31% yield) as a beige powder: mp 164–166 
°C (lit.6 175–176 °C); 1H NMR (DMSO-d6, 500 MHz): δ 1.81–1.86 (1H, m), 2.15–2.17 (1H, m), 2.59–2.71 
(2H, m), 2.89–2.96 (3H, m), 3.65 (3H, s), 6.98 (1H, dd, J = 18.5, 2.0 Hz), 7.26 (1H, d, J = 9.0 Hz), 7.35 (1H, 
d, J = 1.0 Hz), 10.94 (1H, brs); 13C NMR (DMSO-d6, 125 MHz): δ 19.4, 25.1, 25.7, 39.1, 51.6, 107.6, 112.0, 
116.6, 120.0, 122.8, 128.0, 134.3, 134.8, 174.7; LRMS (ES+) m/z: 264.1 [M+H]+; HRMS (ES+) calcd. for 
C14H15NO2Cl [M+H]+ 264.0791, found 264.0791. 
(±)-6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxamide (1c).7 To a solution of 1a (75 mg, 0.30 
mmol) in dry CH2Cl2 (2 mL) containing a few drops of DMF was added N-
hydroxysuccinimide (59 mg, 0.51 mmol) and N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (97 mg, 0.51 mmol) and the mixture stirred for 
2.5 h at room temperature. The resulting suspension was diluted with water 
and extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were 
dried over anhydrous MgSO4 and concentrated. The resultant residue was redissolved in THF (1 mL), 
NH4OH (28%; 1 mL) added and the mixture stirred for 2 h. The resulting orange solution was diluted with 
water and extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with brine (10 
mL), dried over anhydrous MgSO4 and concentrated. Trituration of the residue with CH2Cl2 gave 1c (23 
mg, 31% yield) as an off-white powder: mp 194–196°C (lit.6 203–204 °C); 1H NMR (DMSO-d6, 500 MHz): δ 
1.69–1.75 (1H, m), 2.05–2.09 (1H, m), 2.53–2.64 (2H, m), 2.71–2.87 (3H, m), 6.87 (1H, br s), 6.97 (1H, dd, 
J = 8.0, 1.3 Hz), 7.24 (1H, d, J = 8.5 Hz), 7.35 (1H, s), 7.42 (1H, br s), 10.90 (1H, s); 13C NMR (DMSO-d6, 
125 MHz): δ 19.9, 25.5, 26.7, 40.4, 107.6, 112.0, 116.5, 119.9, 122.8, 128.1, 134.3, 135.7, 176.5; LRMS 
(ES+) m/z: 271.11 [M+Na]+; HRMS (ES+) calcd. for C13H13N2OClNa [M+Na]+ 271.0614, found 271.0616. 
(±)-(6-Chloro-2,3,4,9-tetrahydro-1H-carbazol-2-yl)methanol (1d).6 To a solution of 1a (75 mg, 0.30 
mmol) in dry THF (2 mL) was added portion-wise LiAlH4 (35 mg, 0.93 mmol) and 
the mixture stirred at room temperature for 3 h. A saturated solution of sodium 
potassium tartrate in water was then added and the mixture stirred for 30 min 
before being extracted with EtOAc (3 x 20 mL). The combined organic extracts 
were washed with brine (10 mL), dried over anhydrous MgSO4 and 
concentrated. The resulting residue was triturated with CH2Cl2 to give 1d (30 mg, 
20% yield) as a yellow powder: mp 152–154°C (lit.6 168–169 °C); 1H NMR (CD3OD, 500 MHz): δ 1.50–1.52 
(1H, m), 2.04–2.05 (2H, m), 2.43–2.48 (1H, m), 2.59–2.61 (1H, m), 2.71–2.74 (1H, m), 2.81–2.85 (1H, m), 
3.55–3.62 (2H, m), 6.94 (1H, d, J = 8.0 Hz), 7.17 (1H, d, J = 8.5 Hz), 7.29 (1H, s); 13C NMR (CD3OD, 125 
MHz): δ 21.0, 27.2, 27.4, 38.4, 67.5, 109.8, 112.4, 117.6, 121.2, 125.0, 130.0, 136.2, 136.8; LRMS (ES+) 
m/z: 258.0 [M+Na]+; HRMS (ES+) calcd. for C13H13NO2Cl [M+H]+ 236.0842, found 236.0831.  
(R)-6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid (1e). To a solution of (R)-3-oxo-cyclo-
hexane-1-carboxylic acid (104 mg, 0.12 mmol) in glacial acetic acid (0.5 mL), 
4-chlorophenylhydrazine hydrochloride (136 mg, 0.76 mmol) was added in 
glacial acetic acid (1.0 mL) and the resulting suspension heated at reflux 
overnight. The reaction mixture was cooled, diluted with water (15 mL) and 
extracted with EtOAc (3 x 15 mL). The combined organic extracts were 
washed with water (10 mL), brine (10 mL), dried over anhydrous MgSO4 and 
concentrated. The resulting residue was purified by silica gel column chromatography (20:80:0.5 to 
50:50:0.5 Et2O/petrol/acetic acid) followed by trituration with petrol to give 1e (31 mg, 17% yield) as a 
yellow crystalline solid: mp 242–244°C (lit.6 249–251°C); 1H NMR (CD3OD, 500 MHz): δ 1.86–1.94 (1H, m), 
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2.25–2.27 (1H, m), 2.60–2.66 (1H, m), 2.73–2.78 (1H, m), 2.80–2.86 (1H, m), 2.91 (2H, br d, J = 7.5 Hz), 
6.95 (1H, dd, J = 8.5, 1.8 Hz), 7.17 (1H, d, J = 8.5 Hz), 7.29 (1H, s), 10.2 (1H, br s); 13C NMR (CD3OD, 125 
MHz): δ 20.9, 26.5, 27.5, 41.3, 109.2, 112.5, 117.7, 121.5, 125.1, 129.8, 135.7, 136.2, 178.9; LRMS (ES–) 
m/z: 248.0 [M-H]–; HRMS (ES–) calcd. for C13H11NO2Cl [M-H]– 248.0478, found 248.0486;  [𝛼]!"#!"  +47.7 (c 
1.02, MeOH).  
(S)-6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid (1f). The compound was prepared 
according to the method described for 1e from (S)-3-oxo-cyclohexane-1-
carboxylic acid (101 mg, 0.71 mmol) and 4-chlorophenylhydrazine 
hydrochloride (133.0 mg, 0.74mmol). 1f (59 mg, 33% yield) was obtained as a 
yellow crystalline solid: mp 244–246°C (lit6 249–250°C); 1H NMR (CD3OD, 500 
MHz): δ 1.87–1.95 (1H, m), 2.25–2.28 (1H, m), 2.61–2.67 (1H, m), 2.74–2.79 
(1H. m), 2.81–2.86 (1H, m), 2.95 (2H, d, J = 7.0Hz), 6.95 (1H, dd, J = 8.5, 1.5 
Hz), 7.17 (1H, d, J = 9.0 Hz), 7.29 (1H, d, J = 1.5 Hz), 10.19 (1H, br s); 13C NMR (CD3OD, 125 MHz): δ 
20.9, 26.6, 27.5, 41.4, 109.3, 112.6, 117.7, 121.5, 125.2, 129.8, 135.8, 136.3, 178.9; LRMS (ES+) m/z: 
250.0 [M+H]+; HRMS (ASAP+) calcd. for C13H13NO2Cl [M+H]+ 250.0635, found 250.0643; [𝛼]!"#!"  –45.2 (c 
1.02, MeOH).  
(R)-6-Fluoro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid (1g). The compound was prepared 
according to the method described for 1e from (R)-3-oxo-cyclohexane-1-
carboxylic acid (127 mg, 0.89 mmol) and 4-fluorophenylhydrazine hydrochloride 
(122 mg, 0.75 mmol). 1g (51 mg, 29% yield) was obtained as a yellow powder: 
mp 244–246°C; 1H NMR (CD3OD, 300 MHz): δ 1.87–1.96 (1H, m), 2.24–2.28 
(1H, m), 2.58–2.86 (3H, m), 2.95 (2H, d, J = 7.2 Hz), 6.75 (1H, t, J = 9.0 Hz), 
6.98 (1H, d, J = 9.9 Hz), 7.14–7.18 (1H, m), 10.09 (1H, br s); 13C NMR (CD3OD, 
75 MHz): δ 21.0, 26.6, 27.6, 41.4, 103.1 (d, J = 24.0 Hz), 109.1 (d, J = 26.3 Hz), 109.5 (d, J = 4.6 Hz), 
112.0 (d, J = 10.3 Hz), 128.9 (d, J = 10.3 Hz), 134.3, 136.0, 158.8 (d, J = 230.0 Hz), 179.0; LRMS (ES–) 
m/z: 232.0 [M-H]–; HRMS (ES–) calcd. for C13H11NO2F [M-H]– 232.0774, found 232.0769; [𝛼]!"#!"  +16.2 (c 
0.52, MeOH).  
(R)-6-Iodo-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid (1h). The compound was prepared 
according to the method described for 1e from (R)-3-oxo-cyclohexane-1-
carboxylic acid (84 mg, 0.59 mmol) and 4-iodophenylhydrazine (107 mg, 0.46 
mmol). 1h (24 mg, 15% yield) was obtained as a brown powder: mp 202–
204°C; 1H NMR (CD3OD, 500 MHz): δ 1.88–1.95 (1H, m), 2.25–2.28 (1H, m), 
2.60–2.67 (1H, m), 2.73–277 (1H, m), 2.81–2.86 (1H, m), 2.95 (2H, d, J = 7.0 
Hz), 7.05 (1H, d, J = 9.0 Hz), 7.25 (1H, d, J = 8.0 Hz), 7.65 (1H, s), 10.22 (1H, 
br s); 13C NMR (CD3OD, 125 MHz): δ 20.9, 26.5, 27.5, 41.4, 82.2, 108.8, 113.6, 127.3, 129.8, 131.3, 135.2, 
136.9, 178.9; LRMS (ES–) m/z: 340.0 [M-H]–; HRMS (ES–) calcd. for C13H11NO2I [M-H]–  339.9835, found 
339.9830; [𝛼]!"#!"  –27.7 (c 0.28, MeOH).  
(R)-6-Bromo-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid (1i). The compound was prepared 
according to the method described for 1e from (R)-3-oxo-cyclohexane-1-
carboxylic acid (568 mg, 3.99 mmol) and 4-bromophenylhydrazine hydro-
chloride (908 mg, 4.06 mmol). 1i (943 mg, 80% yield) was obtained as a 
yellow powder: mp 230–232°C;1H NMR (CD3OD, 500 MHz): δ 1.87–1.95 (1H, 
m), 2.25–2.28 (1H, m), 2.61–2.67 (1H, m), 2.74–2.87 (2H, m), 2.96 (2H, d, J = 
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7.0 Hz), 7.08 (1H, d, J = 8.5 Hz), 7.14 (1H, d, J = 8.5 Hz), 7.45 (1H, s); 13C NMR (CD3OD, 125 MHz): δ 
20.9, 26.5, 27.5, 41.4, 109.1, 112.6, 113.0, 120.9, 124.1, 130.5, 135.6, 136.4, 178.9; LRMS (ES–) m/z: 
294.0 [M-H]–; HRMS (ES–) calcd. for C13H11NO2Br [M-H]– 291.9973, found 291.9964; [𝛼]!"#!" +49.0 (c 0.51, 
MeOH). 
(S)-6-Bromo-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid (1j). The compound was prepared 
according to the method described for 1e from (S)-3-oxo-cyclohexane-1-
carboxylic acid (241 mg, 1.70 mmol) and 4-bromophenylhydrazine hydro-
chloride (405 mg, 1.81 mmol). 1j (212 mg, 42% yield) was obtained as a 
yellow powder: mp 236–238°C; 1H NMR (CD3OD, 500 MHz): δ 1.89–1.90 (1H, 
m), 2.24 –2.26 (1H, m), 2.61–2.67 (1H, m), 2.72–2.95 (4H, m), 7.07 (1H, br d, 
J = 8.0 Hz), 7.13 (1H, d, J = 7.5 Hz), 7.44 (1H, s); 13C NMR (CD3OD, 
125MHz): δ 20.9, 26.5, 27.5, 41.4, 109.1, 112.5, 113.0, 120.9, 124.1, 130.4, 135.6, 136.4, 178.9; LRMS 
(ES–) m/z: 292.0 [M-H]–; HRMS (ES–) calcd. for C13H11NO2Br [M-H]– 291.9973, found 291.9980; [𝛼]!"#!"  –
39.6 (c 0.52, MeOH). 
Ethyl (R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylate (1k). To a solution of 4-chlorophenyl-
hydrazine hydrochloride (974 mg, 6.85 mmol) in glacial acetic acid (8 mL) was 
added (R)-3-oxo-1-cyclohexane carboxylic acid (702 mg, 4.94 mmol) and the 
suspension heated at reflux for 6 h. The reaction mixture was cooled, diluted 
with water and extracted with EtOAc (3 x 50 mL). The combined organic 
extracts were washed with water (50 mL), brine (50 mL), dried over 
anhydrous MgSO4 and concentrated. The resulting crude residue was 
redissolved in absolute ethanol (5 mL) containing concentrated H2SO4 (100 µL) and the reaction heated at 
reflux overnight. The solution was cooled, concentrated, made alkaline with saturated NaHCO3(aq) and the 
mixture extracted with EtOAc (3 x 40 mL). The combined organic fractions were washed with brine (40 mL), 
dried over anhydrous MgSO4 and concentrated. The resulting residue was purified by silica gel column 
chromatography (10:0–8:2 Et2O/petrol) to give 1k (877 mg, 64% yield) as a yellow powder: mp 130–132°C; 
1H NMR (CDCl3, 500 MHz): δ 1.29 (3H, t, J = 7.3 Hz), 1.91–1.98 (1H, m), 2.28–2.31 (1H, m), 2.64–2.70 
(1H, m), 2.77–3.05 (4H, m), 4.16–4.21 (2H, m), 7.06 (1H, d, J = 8.0 Hz), 7.16 (1H, d, J = 8.5 Hz), 7.39 (1H, 
s), 7.83 (1H, br s); 13C NMR (CDCl3, 125 MHz): δ 14.4, 20.1, 25.7, 26.3, 40.3, 60.9, 109.5, 111.5, 117.6, 
121.5, 125.1, 128.6, 134.0, 134.4, 175.1; LRMS (ES+) m/z: 278.0 [M+H]+; HRMS (ES+) calcd. for 
C15H17NO2Cl [M+H]+ 278.0948, found 278.0938; [𝛼]!"#!"  +48.4 (c 1.05, MeOH). 
Ethyl (S)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylate (1l). The compound was prepared 
according to the method described for 1k from (S)-3-oxocyclohexane-1-
carboxylic acid (272 mg, 1.91 mmol) and 4-chlorophenylhydrazine hydro-
chloride (340 mg, 1.89 mmol). 1l was obtained (184 mg, 35% yield) as a pale 
yellow solid: mp 130–132°C; 1H NMR (CDCl3, 500 MHz): δ 1.29 (3H, t, J = 7.3 
Hz), 1.92–1.98 (1H, m), 2.29–2.31 (1H, m), 2.65–2.71 (1H, m), 2.77–3.05 (4H, 
m), 4.17–4.23 (2H, m), 7.06 (1H, dd, J = 8.0, 1.5 Hz), 7.17 (1H, d, J = 9.0 Hz), 
7.40 (1H, s), 7.81 (1H, br s); 13C NMR (CDCl3, 125 MHz): δ 14.4, 20.1, 25.7, 26.3, 40.3, 60.9, 109.5, 111.5, 
117.6, 121.6, 125.1, 128.6, 134.0, 134.4, 175.1; LRMS (ES–) m/z: 276.0 [M-H]–; HRMS (ES–) calcd. for 
C15H15NO2Cl [M-H]– 276.0791, found 276.0780; [𝛼]!"#!"  –42.8 (c 1.03, MeOH). 
Ethyl (R)-6-bromo-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylate (1m). The compound was prepared 
according to the method described for 1k from (R)-3-oxocyclohexane-1-carboxylic acid (2.28 g, 10.18 
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mmol) and 4-bromophenylhydrazine hydrochloride (1.45 g, 10.17 mmol). 1m 
(1.99 g, 58% yield) was obtained as a yellow powder: mp 144–146°C; 1H 
NMR (CDCl3, 500 MHz): δ 1.29 (3H, t, J = 7.0 Hz), 1.92–1.98 (1H, m), 2.28–
2.31 (1H, m), 2.65–2.70 (1H, m), 2.77–3.05 (4H, m), 4.17–4.23 (2H, m, CH2), 
7.11 (1H, d, J = 8.5 Hz), 7.18 (1H, d, J = 8.5 Hz), 7.55 (1H, s), 7.84 (1H, br s); 
13C NMR (CDCl3, 125 MHz): δ 14.5, 20.1, 25.7, 26.4, 40.3, 61.0, 109.5, 112.1, 112.7, 120.7, 124.2, 129.3, 
133.9, 134.8, 175.2; LRMS (ES+) m/z: 362.0 [M+K]+; HRMS (ES+) calcd. for C15H17NO2Br [M+H]+ 322.0443, 
found 322.0443; [𝛼]!"#!"  +49.5 (c 1.04, MeOH). 
Ethyl (S)-6-bromo-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylate (1n). The compound was prepared 
according to the method described for 1k from (S)-3-oxocyclohexane-1-
carboxylic acid (227 mg, 1.60 mmol) and 4-bromophenylhydrazine hydro-
chloride (387 mg, 1.73 mmol). 1n (183 mg, 35% yield) was obtained as a 
yellow powder: mp 136–138°C; 1H NMR (CDCl3, 500 MHz): δ 1.29 (3H, d, J = 
7.3 Hz), 1.90–1.98 (1H, m), 2.28–2.31 (1H, m), 2.64–2.70 (1H, m), 2.76–3.04 
(4H, m), 4.16–4.23 (2H, m, CH2), 7.11 (1H, d, J = 8.5 Hz), 7.18 (1H, dd, J = 8.0, 1.5 Hz), 7.55 (1H, s), 7.84 
(1H, br s); 13C NMR (CDCl3, 125 MHz): δ 14.4, 20.1, 25.6, 26.3, 40.3, 60.9, 109.4, 112.0, 112.6, 120.7, 
124.1, 129.3, 133.8, 134.7, 175.1; LRMS (ES–) m/z: 320.0 [M-H]–; HRMS (ES–) calcd. for C15H15NO2Br [M-
H]– 320.0286, found 320.0288; [𝛼]!"#!"  –39.3 (c 0.98, MeOH).  
(R)-9-(2-Amino-2-oxoethyl)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid (2a). To a 
solution of 1k (163 mg, 0.59 mmol) in dry DMF (1.0 mL) was added Cs2CO3 (304 
mg, 0.93 mmol) and the suspension stirred at room temperature for 15 min. A 
solution of iodoacetamide (152 mg, 0.82 mmol) in dry DMF (0.5 mL) was added 
drop wise and the mixture stirred at 60°C under N2 overnight. The reaction was 
quenched with 1 M HCl (20 mL) and extracted with EtOAc (3 x 20 mL). The 
combined extracts were washed with 0.5 M HCl (2 x 20 mL), brine (20 mL), dried 
over anhydrous MgSO4 and concentrated. The crude residue was purified by 
silica gel column chromatography (6:4:0–9:0:1 Et2O/petrol/MeOH) to give ethyl (R)-9-(2-amino-2-oxoethyl)-
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylate as a yellow powder. The compound was dissolved 
in absolute EtOH (1 mL) and an aqueous solution of NaOH (2 M, 400 µL) added. The resulting suspension 
was stirred at room temperature overnight. The reaction mixture was concentrated, diluted with water and 
washed with CH2Cl2 (10 mL). The aqueous layer was acidified with 1 M HCl and extracted with EtOAc (3 x 
10 mL). The combined organic extracts were washed with water (10 mL), brine (10 mL), dried over 
anhydrous MgSO4 and concentrated. The resulting residue was triturated with Et2O to give 2a (11 mg, 6% 
yield) as a white solid: mp > 260°C (dec.); 1H NMR (DMSO-d6, 500 MHz): δ 1.74–1.76 (1H, m), 2.17–2.20 
(1H, m), 2.60–2.63 (1H, m), 2.73–2.92 (4H, m), 4.68 (2H, s), 7.05 (1H, d, J = 9.0 Hz), 7.23 (1H, br s), 7.33 
(1H, d, J = 8.5 Hz), 7.41 (1H, s), 7.53 (1H, br s); 13C NMR (DMSO-d6, 125 MHz): δ 19.7, 24.0, 25.6, 39.40, 
45.2, 107.9, 110.5, 116.7, 120.1, 123.3, 127.7, 135.4, 136.7, 169.4, 176.0; LRMS (ES+) m/z: 329.0 
[M+Na]+; HRMS (ES+) calcd. for C15H16N2O3Cl [M+H]+ 307.0849, found 307.0847; [𝛼]!"#!"  +10.4 (c 0.6, 
DMSO).  
(S)-9-(2-Amino-2-oxoethyl)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-
carboxylic acid (2b). The compound was prepared according to the method 
described for 2a from 1l (170 mg, 0.61 mmol), iodoacetamide (104 mg, 0.56 
mmol) and Cs2CO3 (260 mg, 0.80 mmol) in dry DMF (1.5 mL). Following ethyl 
ester hydrolysis, 2b (7.4 mg, 4% yield) was obtained as a white powder: mp > 
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260°C (dec.);1H NMR (DMSO-d6, 500 MHz): δ 1.74–1.76 (1H, m), 2.18–2.20 (1H, m), 2.61–2.62 (1H, m), 
2.77–2.91 (4H, m), 4.68 (2H, s, CH2), 7.05 (1H, d, J = 8.5 Hz), 7.23 (1H, br s), 7.34 (1H, d, J = 8.0 Hz), 
7.40 (1H, s), 7.53 (1H, br s); 13C NMR (DMSO-d6, 125 MHz): δ 19.7, 24.0, 25.7, 39.5, 45.2, 107.9, 110.6, 
116.7, 120.1, 123.3, 127.7, 135.4, 136.7, 169.5, 176.0; LRMS (ES+) m/z: 329.0 [M+Na]+; HRMS (ES+) 
calcd. for C15H15N2O3ClNa [M+Na]+ 329.0669, found 329.0683; [𝛼]!"#!"  –9.2 (c 0.29, DMSO). 
(R)-2-(6-Bromo-2-(ethoxycarbonyl)-1,2,3,4-tetrahydro-9H-carbazol-9-yl)acetic acid (3a). To a solution 
of 1m (642 mg, 2.31 mmol) in dry DMF (1 mL) was added Cs2CO3 (581 mg, 
1.78 mmol) and tert-butyl bromoacetate (302 mg, 1.55 mmol) and the mixture 
stirred at 60°C under N2 for 19 h. The reaction mixture was quenched with 1 
M HCl (20 mL) and extracted with CH2Cl2 (3 x 20 mL). The combined 
extracts were washed with 0.5 M HCl (3 x 20 mL), brine (20 mL), dried over 
anhydrous MgSO4 and concentrated. The resulting crude residue was 
purified by silica gel column chromatography (2:8–5:5 Et2O/petrol) to give 
(R)-9-(2-(tert-butoxy)-2-oxoethyl)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylate, which was 
treated with TFA (1 mL). Following reaction for 1 h, the TFA was evaporated under a stream of N2 to afford 
3a (402 mg, 83% yield) as a yellow powder: mp 180–182°C; 1H NMR (DMSO-d6, 500 MHz): δ 1.22 (3H, t, J 
= 6.8 Hz, CH3), 1.77–1.78 (1H, m), 2.17–2.19 (1H, m), 2.63–2.94 (5H, m), 4.11–4.15 (2H, m), 4.92 (2H, s), 
7.17 (1H, d, J = 8.0), 7.35 (1H, d, J = 8.5 Hz), 7.55 (1H, br s), 13.09 (1H, br s); 13C NMR (DMSO-d6, 125 
MHz): δ 14.1, 19.4, 23.7, 25.6, 39.3, 44.1, 60.2, 108.1, 110.7, 116.8, 120.3, 123.5, 127.7, 135.3, 136.1, 
170.3, 174.2; LRMS (ES–) m/z: 380.0 [M-H]–; HRMS (ES–) calcd. for C17H17NO4Br 378.0341 [M-H]–, found. 
378.0324; [𝛼]!"#!"  +25.7 (c 1.00, MeOH). 
2-(6-Chloro-2-(ethoxycarbonyl)-3,4-dihydro-1H-carbazol-9(2H)-yl)acetic acid (3c). The compound was 
prepared according to the method described for 3a from 1k (642 mg, 2.31 
mmol), tert-butyl bromoacetate (375 µL, 495 mg, 2.54 mmol) and Cs2CO3 
(1.03 g, 3.15 mmol) in DMF (4 mL). Following tert-butyl ester deprotection 3c 
(331 mg, 43% yield) was obtained as an pale yellow powder: mp 180–182°C; 
1H NMR (DMSO-d6, 500 MHz): δ 1.22 (3H, t, J = 7.0 Hz), 1.75–1.80 (1H, m), 
2.17–2.19 (1H, m), 2.60–2.65 (1H, m), 2.73–2.94 (4H, m), 4.13 (2H, t, J = 6.8 
Hz), 4.92 (2H, d, J = 2.0 Hz), 7.05 (1H, dd, J = 8.5, 1.8 Hz), 7.39 (1H, d, J = 
8.5 Hz), 7.41 (1H, d, J = 2.0 Hz), 13.00 (1H, br s); 13C NMR (DMSO-d6, 125 
MHz): δ 14.1, 19.5, 23.7, 25.6, 39.3, 44.1, 60.2, 108.1, 110.7, 116.8, 120.3, 123.5, 127.7, 135.3, 136.1, 
170.3, 174.2; LRMS (ES+) m/z: 358.0 [M+Na]+; HRMS (ES+) calcd. for C17H18NO4ClNa [M+Na]+ 358.0822, 
found 358.0815; [𝛼]!"#!"  +2.0 (c 0.97, MeOH).  
(R)-9-(2-Amino-2-oxoethyl)-6-bromo-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid (4a). To a 
solution of 3a (87.9 mg, 0.23 mmol) in dry CH2Cl2 (2 mL) was added NHS (41 
mg, 0.36 mmol) and EDC (79 mg, 0.41mmol) and the reaction mixture stirred 
for 1 h at room temperature. The CH2Cl2 was evaporated under nitrogen and 
the resulting residue redissolved in THF (2 mL). Aqueous NH4OH solution 
(28%; 1 mL) was added and the mixture stirred overnight at room 
temperature. The resulting precipitate was collected by vacuum filtration 
(washing with water) and then triturated with Et2O. The resulting ethyl (R)-9-
(2-amino-2-oxoethyl)-6-bromo-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylate (29 mg, 0.08 mmol) was 
dissolved in absolute EtOH (2 mL), an aqueous NaOH solution (2 M; 500 µL) added and the suspension 
stirred at room temperature overnight. The reaction mixture was concentrated, diluted with water, acidified 
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with 1 M HCl and extracted with EtOAc (3 x 10 mL). The combined extracts were washed with water (10 
mL), brine (10 mL), dried over anhydrous MgSO4 and concentrated. The resulting crude residue was 
triturated with Et2O to give 4a (12 mg, 14% yield) as a yellow powder: mp > 250°C (dec.); 1H NMR (DMSO-
d6, 300 MHz): δ 1.70–1.76 (1H, m), 2.16–2.20 (1H, m), 2.60–2.92 (5H, m), 4.69 (2H, s), 7.16 (1H, d, J = 8.7 
Hz), 7.25 (1H, br s), 7.29 (1H, d, J = 8.7 Hz), 7.54 (2H, br s), 12.44 (1H, br s); 13C NMR (DMSO-d6, 75 
MHz): δ 19.7, 23.9, 25.6, 39.3, 45.2, 107.8, 111.1, 111.2, 119.7, 122.7, 128.4, 135.6, 136.5, 169.4, 176.0; 
LRMS (ES+) m/z: 373.0 [M+Na]+; HRMS (ES+) calcd. for C15H15N2O3BrNa [M+Na]+ 373.0164, found 
373.0182; [𝛼]!"#!"  +12.9 (c 0.64, DMSO). 
(S)-9-(2-amino-2-oxoethyl)-6-bromo-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid (4b). (S)-2-(6-
bromo-2-(ethoxycarbonyl)-1,2,3,4-tetrahydro-9H-carbazol-9-yl)acetic acid (3b) 
was prepared according to the method described for 3a from 1n (145 g, 0.45 
mmol), Cs2CO3 (220 mg, 0.67 mmol) and tert-butyl bromoacetate (115 mg, 
0.59 mmol). Following TFA deprotection of the tert-butyl ester, (S)-2-(6-bromo-
2-(ethoxycarbonyl)-1,2,3,4-tetrahydro-9H-carbazol-9-yl)acetic acid (92 mg, 
0.24 mmol) was subsequently reacted with NHS (40 mg, 0.34 mmol) and EDC 
(72 mg, 0.38 mmol) according to the method described for 4a. Ethyl ester 
hydrolysis in an aqueous solution of NaOH (2 M; 300 µL) in absolute ethanol (4 mL) yielded 4b (28 mg, 
33% yield) as a yellow powder: mp > 250°C (dec.); 1H NMR (DMSO-d6, 500 MHz): δ 1.75–1.76 (1H, m), 
2.17–2.20 (1H, m), 2.59–2.62 (1H, m), 2.73–2.92 (4H, m), 4.69 (2H, s, CH2), 7.16 (1H, d, J = 8.5 Hz), 7.23 
(1H, br s), 7.29 (1H, d, J = 8.5 Hz), 7.52 (1H, br s), 7.54 (1H, s), 12.42 (1H, br s); 13C NMR (DMSO-d6, 125 
MHz): δ 19.7, 23.9, 25.6, 39.3, 45.2, 107.8, 111.1, 111.2, 119.7, 122.7, 128.3, 135.6, 136.5, 169.4, 175.9; 
LRMS (ES+) m/z: 373.0 [M+Na]+; HRMS (ES+) calcd. for C15H15N2O3BrNa [M+Na]+ 373.0164, found 
373.0174; [𝛼]!"#!"  +4.4 (c 0.71, DMSO). 
(R)-9-(2-((carboxymethyl)amino)-2-oxoethyl)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic 
acid (5a). To a solution containing 3c (147 mg, 0.44 mmol), glycine 
methyl ester hydrochloride (69 mg, 0.55 mmol) and HATU (221 mg, 0.58 
mmol) in dry DMF (1 mL) was added DIPEA (250 µL, 1.44 mmol) 
dropwise and the resulting mixture stirred at room temperature overnight 
under N2. The reaction mixture was diluted water and extracted with 
EtOAc (3 x 15 mL). The combined extracts were washed with 0.5 M HCl 
(3 x 15 mL), sat. NaHCO3 (15 mL) and brine (15 mL) before being dried 
over anhydrous MgSO4 and concentrated. The resulting residue 
containing ethyl (R)-6-chloro-9-(2-((2-methoxy-2-oxoethyl)amino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-
carbazole-2-carboxylate was dissolved in absolute EtOH (1 mL), an aqueous solution of NaOH (2 M, 400 
µL) added and the suspension stirred at room temperature overnight. The reaction mixture was 
concentrated, diluted with water and then washed with CH2Cl2 (15 mL). The aqueous layer was acidified (1 
M HCl) and extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with water (15 
mL) and brine (15 mL) before being dried over anhydrous MgSO4 and concentrated. The resulting residue 
was purified by silica gel column chromatography (0:10:0–1:9:0.005 MeOH/CH2Cl2/acetic acid) to give 5a 
(96 mg, 60% yield) as an off-white powder: mp 220–222°C; 1H NMR (CH3OD, 500 MHz): δ 1.92–1.99 (1H, 
m), 2.26–2.29 (1H, m), 2.64–2.70 (1H, m), 2.76–2.79 (1H, m), 2.89–2.98 (3H, m), 3.89 (2H, s), 4.77 (2H, s), 
7.04 (1H, d, J = 8.5 Hz), 7.23 (1H, d, J = 9.0 Hz), 7.35 (1H, s), 7.96 (1H, br s); 13C NMR (CH3OD, 125 
MHz): δ 20.9, 25.2, 27.1, 41.2, 41.8, 46.7, 110.5, 111.0, 118.2, 122.1, 126.1, 129.8, 137.0, 137.2, 171.4, 
172.6, 178.6; LRMS (ES–) m/z: 363.0 [M-H]–; HRMS (ES–) calcd. for C17H16N2O5Cl [M-H]– 363.0748, found 
363.0733; [𝛼]!"#!"  –5.7 (c 0.50, MeOH). 
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(R)-6-bromo-9-(2-((carboxymethyl)amino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic 
acid (5b). The compound was prepared according to the method described for 5a from 3a (108 mg, 0.28 
mmol), glycine methyl ester hydrochloride (49 mg, 0.39 mmol), HATU 
(137 mg, 0.36 mmol) and DIPEA (160 µL, 0.92 mmol) in dry DMF (1 mL). 
Following ester deprotection in an aqueous solution of NaOH (2 M; 300 
µL) and absolute ethanol (1 mL), 5b (46 mg, 40% yield) was obtained as 
an off white powder: mp 238–240°C; 1H NMR (CH3OD, 500 MHz): δ 
1.92–1.95 (1H, m), 2.26–2.28 (1H, m), 2.64–2.68 (1H, m), 2.76–2.79 (1H, 
m), 2.89–2.98 (3H, m), 3.89 (2H, s), 4.76 (2H, s), 7.17–7.18 (2H, m), 7.50 
(1H, s), 8.01 (1H, br s); 13C NMR (CH3OD, 125 MHz): δ 20.9, 25.1, 27.2, 41.1, 41.8, 46.6, 110.4, 111.5, 
113.5, 121.3, 124.7, 130.4, 137.1, 137.3, 171.3, 172.7, 178.6; LRMS (ES–) m/z: 407.0 [M-H]–; HRMS (ES–) 
calcd. for C17H16N2O5Br [M-H]– 407.0243, found 407.0256; [𝛼]!"#!"  +23.1 (c 0.59, MeOH). 
(R)-6-chloro-9-(2-(ethylamino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid (5c). 
The compound was prepared according to the method described for 5a from 
3c (140 mg, 0.42 mmol), ethylamine hydrochloride (46 mg, 0.56 mmol), HATU 
(211 mg, 0.56 mmol) and DIPEA (200 µL, 1.15 mmol) in dry DMF (1 mL). 
Ester deprotection in an aqueous solution of NaOH (2 M; 400 µL) and 
absolute ethanol (1 mL) afforded 5c (54 mg, 38% yield) as an off-white 
powder: mp 246–248°C; 1H NMR (DMSO-d6, 500 MHz): δ 1.02 (3H, t, J = 7.0 
Hz), 1.75–1.76 (1H, m), 2.17–2.20 (1H, m), 2.61–2.62 (1H, m), 2.77–2.93 (4H, 
m), 3.08–3.12 (2H, m), 4.69 (2H, s), 7.05 (1H, d, J = 8.0 Hz), 7.34 (1H, d, J = 
9.0 Hz), 7.40 (1H, s), 8.12 (1H, s), 12.43 (1H, br s); 13C NMR (DMSO-d6, 125 MHz): δ 14.6, 19.7, 24.1, 
25.6, 33.5, 39.6, 45.6, 108.0, 110.6, 116.7, 120.1, 123.3, 127.7, 135.4, 136.7, 167.0, 176.0; LRMS (ES+) 
m/z: 357.0 [M+Na]+; HRMS (ES+) calcd. for C17H19N2O3ClNa [M+Na]+ 357.0982, found 357.0970; [𝛼]!"#!"  
+2.7 (c 0.52, MeOH). 
 (R)-9-(2-((4-(2-amino-2-oxoethyl)phenyl)amino)-2-oxoethyl)-6-chloro-2,3,4,9-tetrahydro-1H-
carbazole-2-carboxylic acid (5d). The compound was prepared 
according to the method described for 5a from 3c (125 mg, 0.37 
mmol), 2-(4-aminophenyl)acetamide (73 mg, 0.48 mmol), HATU 
(181 mg, 0.48 mmol) and DIPEA (230 µL, 1.32 mmol) in dry DMF 
(1 mL). Ester deprotection in an aqueous solution of NaOH (2 M; 
140 µL) and absolute ethanol (1 mL) gave 5d (29 mg, 31% yield) as 
a white powder: mp > 260°C (dec.);1H NMR (DMSO-d6, 500 MHz): 
δ 1.76–1.78 (1H, m), 2.18–2.20 (1H, m), 2.63–2.96 (5H, m), 3.31 
(2H, s), 4.95 (2H, s), 6.82 (2H, s), 7.06 (1H, d, J = 7.5 Hz), 7.19 
(2H, d, J = 8.0 Hz), 7.39–7.42 (2H, m), 7.49 (2H, d, J = 8.0 Hz), 10.34 (1H, s), 12.50 (1H, br s); 13C NMR 
(DMSO-d6, 125 MHz): δ 19.7, 24.0, 25.7, 39.3, 41.7, 46.0, 108.1, 110.6, 116.8, 119.1, 120.2, 123.4, 127.7, 
129.4, 131.7, 135.5, 136.8, 136.9, 166.1, 172.2, 176.0; LRMS (ES–) m/z: 438.0 [M-H]–; HRMS (ES–) calcd. 
for C23H21N3O4Cl [M-H]– 438.1221, found 438.1215; [𝛼]!"#!"  +3.77 (c 0.53, DMSO). 
(R)-6-bromo-9-(2-(((1-(BOC)piperidin-4-yl)methyl)amino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-
carbazole-2-carboxylic acid (5e). The compound was prepared according to the method described for 5a 
from 3a (216 mg, 0.57 mmol), tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (159 mg, 0.74 mmol), 
HATU (301 mg, 0.79 mmol) and DIPEA (350 µL, 2.01 mmol) in dry DMF (2 mL). Ester deprotection in an 
aqueous solution of NaOH (2 M; 300 µL) and absolute ethanol (1 mL) provided 5e (68 mg, 36% yield) as a 
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pale yellow powder: mp 158–160°C; 1H NMR (DMSO-d6, 500 
MHz): δ 0.95–0.99 (2H, m), 1.39 (9H, s), 1.57–1.59 (3H, m), 
1.74–1.77 (1H, m), 2.17–2.20 (1H, m), 2.61–2.64 (3H, m), 2.73–
2.91 (3H, m), 2.94–2.97 (3H, m), 3.91 (2H, br d, J = 9.5 Hz), 4.72 
(2H, s), 7.16 (1H, dd, J = 9.0, 1.8 Hz), 7.30 (1H, d, J = 9.0 Hz), 
7.54 (1H, d, J = 1.5 Hz), 8.16 (1H, br t, J = 5.8 Hz), 12.44 (1H, br 
s); 13C NMR (DMSO-d6, 125 MHz): δ 19.7, 24.0, 25.7, 28.1, 29.4, 
35.7, 39.4, 44.0, 45.5, 78.5, 107.9, 111.2, 111.3, 119.8, 122.8, 
128.4, 135.6, 136.6, 153.8, 167.5, 176.0; LRMS (ES+) m/z: 570.0 [M+Na]+; HRMS (ES+) calcd. for 
C26H34N3O5BrNa [M+Na]+ 570.1580, found 570.1604; [𝛼]!"#!"  +8.5 (c 0.52, MeOH). 
(R)-6-bromo-9-(2-oxo-2-((piperidin-4-ylmethyl)amino)ethyl)-2,3,4,9-tetrahydro-1H-carbazole-2-
carboxylic acid.TFA salt (5f). Neat TFA (1 mL) was added to 5e (42 
mg, 0.076 mmol) and the mixture stirred at room temperature for 1 h. 
The TFA was evaporated under a stream of N2 and the resulting 
residue triturated with petrol to give 5f (39 mg, 91% yield) as a yellow 
powder: mp 212–214°C; 1H NMR (CH3OD, 500 MHz): δ 1.29–1.37 
(2H, m), 1.77–1.84 (3H, m), 1.98–1.99 (1H, m), 2.27–2.30 (1H, m), 
2.70–2.81 (2H, m), 2.89–2.94 (5H, m), 3.13 (2H, d, J = 6.0 Hz), 3.31–
3.36 (2H, m), 4.76 (2H, d, J = 3.0 Hz), 7.19 (2H, br s), 7.54 (1H, s); 13C 
NMR (CH3OD, 125 MHz): δ 20.8, 25.3, 27.1, 27.6, 35.2, 41.0, 44.8, 45.0, 46.8, 110.4, 111.4, 113.5, 121.4, 
124.7, 130.5, 137.1, 137.3, 171.0, 178.5; LRMS (ES+) m/z: 448.0 [M+H]+; HRMS (ES+) calcd. for 
C21H27N3O3Br [M+H]+ 448.1236, found 448.1222; [𝛼]!"#!"  +4.6 (c 0.51, MeOH). 
(R)-9-(2-((2-amino-2-oxoethyl)amino)-2-oxoethyl)-6-bromo-2,3,4,9-tetrahydro-1H-carbazole-2-
carboxylic acid (5g). The compound was prepared according to the 
method described for 5a from 3a (122 mg, 0.32 mmol), glycinamide 
hydrochloride (60 mg, 0.55 mmol), HATU (166 mg, 0.44 mmol) and 
DIPEA (230 µL, 1.32 mmol) in dry DMF (1 mL). Ester hydrolysis in an 
aqueous solution of NaOH (2 M; 300 µL) and absolute ethanol (1 mL) 
afforded 5g (8.5 mg, 6.5% yield) as an off-white powder: mp 232–
234°C; 1H NMR (DMSO-d6, 500 MHz): δ 1.74–1.76 (1H, m), 2.17–2.19 
(1H, m), 2.61–2.63 (1H, m), 2.73–2.95 (4H, m), 3.66 (2H, d, J = 5.5 Hz, CH2), 4.80 (2H, s, CH2), 7.05 (1H, 
s), 7.15 (1H, d, J = 8.5 Hz), 7.31–7.35 (2H, m), 7.54 (1H, s), 8.26 (1H, br s), 12.40 (1H, br s); 13C NMR 
(DMSO-d6, 125 MHz): δ 19.6, 23.9, 25.7, 39.8, 41.8, 45.3, 107.9, 111.2, 119.7, 122.7, 128.4, 135.6, 136.6, 
167.7, 170.4, 175.9; LRMS (ES–) m/z: 408.0 [M-H]–; HRMS (ES–) calcd. for C17H17N3O4Br [M-H]– 406.0402, 
found 406.0404; [𝛼]!"#!"  –9.6 (c 0.19, DMSO).  
(R)-6-bromo-9-(2-((4-carbamoylbenzyl)amino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-2-
carboxylic acid (5h). The compound was prepared according to the method described for 5a from 3a (155 
mg, 0.41 mmol), 4-(aminomethyl)benzamide (74 mg, 0.49 
mmol), HATU (227 mg, 0.60 mmol) and DIPEA (250 µL, 1.44 
mmol) in dry DMF (1 mL). Following ester deprotection in an 
aqueous solution of NaOH (2 M; 300 µL) and absolute ethanol 
(1 mL), the mixture was acidified and the resulting precipitate 
collected by vacuum filtration. The precipitate was basified with 
1 M NaOH, dissolved in water and filtered through a 1 cm plug 
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of reverse phase silica, washing with water. The aqueous solution was acidified and the precipitate 
collected by vacuum filtration, washing with ethanol and petrol to give 5h (7.0 mg, 4% yield) as an off-white 
powder: mp > 230°C (dec); 1H NMR (DMSO-d6, 500 MHz): δ 1.75–1.77 (1H, m), 2.18–2.20 (1H, m), 2.62–
2.63 (1H, m), 2.73–2.97 (4H, m), 4.34 (2H, s), 4.83 (2H, s), 7.17 (1H, br s), 7.28–7.38 (4H, m), 7.55 (1H, s), 
7.82 (2H, d, J = 7.5 Hz), 7.93 (1H, br s), 8.78 (1H, br s), 12.44 (1H, br s); 13C NMR (DMSO-d6, 125 MHz): δ 
19.7, 24.1, 25.7, 40.2, 42.0, 45.6, 108.1, 111.2, 111.4, 119.8, 122.8, 126.9, 127.6, 128.5, 132.9, 135.7, 
136.6, 142.5, 167.7, 176.1; LRMS (ES–) m/z: 482.0 [M-H]–; HRMS (ES–) calcd. for C23H21N3O4Br [M-H]– 
482.0715, found 482.0717; [𝛼]!"#!"  +7.4 (c 0.48, DMSO). 
(R)-9-(2-((1-(2-amino-2-oxoethyl)piperidin-4-yl)amino)-2-oxoethyl)-6-bromo-2,3,4,9-tetrahydro-1H-
carbazole-2-carboxylic acid potassium salt (5i). The compound 
was prepared according to the method described for 5a from 3a 
(83 mg, 0.22 mmol), 2-(4-amino-1-piperidinyl) acetatmide 
dihydrochloride (70 mg, 0.25 mmol), HATU (111 mg, 0.29 mmol) 
and DIPEA (200 µL, 1.15 mmol) in dry DMF (1 mL). Following 
deprotection in an aqueous solution of KOH (1 M, 38 µL, 0.038 
mmol) in THF:EtOH:H2O (1:1:1; 1 mL) the mixture was 
concentrated, washed with CH2Cl2 (2 x 2 mL) and the aqueous 
layer lyophilized. The resulting residue was triturated with ether, redissolved in methanol, filtered and 
concentrated to give the potassium salt of 5i (13 mg, 64% yield) as an off-white gum: 1H NMR (DMSO-d6, 
500 MHz): δ 1.47–1.52 (2H, m), 1.68–1.71 (3H, m), 2.06–2.11 (3H, m), 2.27–2.29 (1H, m), 2.48–2.50 (1H, 
m), 2.65–2.73 (5H, m), 2.81 (2H, s), 3.49–3.51 (1H, m), 4.67 (2H, d, J = 3.5 Hz), 7.09–7.11 (2H, m), 7.16 
(1H, br s), 7.25 (1H, d, J = 8.5 Hz), 7.46 (1H, d, J = 2.0 Hz), 8.28 (1H, br d, J = 7.0 Hz); 13C NMR (DMSO-
d6, 125 MHz): δ 20.4, 25.6, 27.2, 31.2, 43.0, 45.5, 45.8, 52.1, 61.4, 108.1, 110.9, 119.4, 122.0, 128.8, 
135.0, 139.2, 166.7, 171.9, 177.4; LRMS (ES+) m/z: 491.0 [M-K+H]+; HRMS (ES+) calcd. for C22H28N4O4Br 
[M-K+H]+ 491.1294, found 491.1310; [𝛼]!"#!"  –4.3 (c 1.28, MeOH). 
(R)-6-bromo-9-(2-(((R)-5-((tert-butoxycarbonyl)amino)-1-carboxypentyl)amino)-2-oxoethyl)-2,3,4,9-
tetrahydro-1H-carbazole-2-carboxylic acid (5j). The compound was 
prepared according to the method described for 5a with the following 
modification. Compound 3a (96 mg, 0.25 mmol) was pre-activated with 
HATU (136 mg, 0.36 mmol) and DIPEA (160 µL, 0.92 mmol) in dry 
CH2Cl2 (1 mL) containing a few drops of DMF, before a solution of NH2-
(D)-Lys-(BOC)-OtBu.HCl (107 mg, 0.32 mmol) in dry CH2Cl2 (1 mL) was 
added. Ester deprotection with LiOH.H2O (27 mg, 0.63 mmol) in 
THF:EtOH:H2O (1:1:1; 1 mL) yielded 5j (98 mg, 57% yield) as a yellow 
solid: mp 78–80°C; 1H NMR (DMSO-d6, 500 MHz): δ 1.28 (4H, br s), 
1.38 (9H, s), 1.59–1.61 (1H, m), 1.71–1.72 (2H, m), 2.17–2.18 (1H, m), 
2.61–2.96 (7H, m), 4.14 (1H, br s), 4.74–4.80 (2H, m), 6.75 (1H, br s), 
7.16 (1H, d, J = 8.5 Hz), 7.31 (1H, t), 7.54 (1H, s), 8.48 (1H, t), 12.54 
(1H, br s); 13C NMR (DMSO-d6, 75 MHz): δ 19.7, 22.7, 24.0, 25.7, 28.3, 29.1, 30.8, 39.4, 39.8, 45.2, 52.1, 
77.4, 107.9, 111.2, 111.3, 119.7, 122.7, 128.4, 135.6, 136.6, 155.6, 167.5, 173.4, 176.0; LRMS (ES–) m/z: 
580.0 [M-H]–; HRMS (ES–) calcd. for C26H33N3O7Br [M-H]– 578.1502, found 578.1504; [𝛼]!"#!"  +2.4 (c 2.84, 
MeOH). 
(R)-6-bromo-9-(2-(((S)-1-carboxy-3-methylbutyl)amino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-
2-carboxylic acid (5k). The compound was prepared according to the method described for 5a from 3a 
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(249 mg, 0.654 mmol), NH2-(L)-Leu-(OtBu).HCl (194 mg, 0.87 mmol), 
HATU (339 mg, 0.891 mmol) and DIPEA (450 µL, 2.58 mmol) in dry DMF 
(5 mL). Following ethyl ester hydrolysis in an aqueous solution of NaOH 
(2 M; 500 µL) in EtOH:H2O (1:1; 3 mL), the resulting residue was treated 
with TFA (1 mL) and the mixture stirred for 1 h. Removal of the TFA 
under a stream of N2 and trituration of the residue with toluene gave 5k 
(39 mg, 30% yield); 1H NMR (CD3OD, 500 MHz): δ 0.82–0.90 (6H, m), 
1.25 (1H, br s), 1.52–1.59 (2H, m), 1.86–1.93 (1H, m), 2.25–2.28 (1H, 
m), 2.63–2.69 (1H, m), 2.74–2.78 (1H, m) 2.86–2.93 (3H, m), 4.23–4.37 (1H, m), 4.76 (2H, s), 7.13 (1H, d, 
J = 9.0 Hz), 7.16 (1H, d, J = 8.5 Hz), 7.48 (1H, s); 13C NMR (CD3OD, 125 MHz): δ 21.0, 23.5, 25.4, 26.1, 
27.1, 41.5, 46.6, 49.2, 52.1, 110.3, 111.7, 113.5, 121.5, 124.5, 130.5, 137.2, 137.4, 170.8, 175.6, 178.6; 
LRMS (ES–) m/z: 465.0 [M-H]–; HRMS (ES–) calcd. for C22H20N6OBr [M–H]– 463.0882, found 463.0879; 
[𝛼]!"#!" +5.22 (c 0.46, MeOH). 
(R)-6-bromo-9-(2-(((R)-1-carboxy-2-phenylethyl)amino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-
2-carboxylic acid (5l). The compound was prepared according to the 
method described for 5a from 3a (134 mg, 0.35 mmol), NH2-(D)-Phe-
(OMe).HCl (92 mg, 0.43 mmol), HATU (173 mg, 0.46 mmol) and DIPEA 
(230 µL, 1.32 mmol) in dry DMF (1 mL). Global ester deprotection in an 
aqueous solution of NaOH (2 M; 300 µL) and absolute ethanol (2 mL) 
afforded 5l (69 mg, 39% yield) as an off-white powder: mp 194-196 °C; 
1H NMR (DMSO-d6, 500 MHz): δ 1.72-1.73 (1H, m), 2.15 (1H, m), 2.58-
2.86 (5H, m), 2.86-2.90 (1H, m), 3.06-3.09 (1H, m), 4.41 (1H, br s), 
4.65-4.77 (2H, m), 7.11-7.25 (7H, m), 7.52 (1H, s), 8.36 (1H, br s), 12.70 
(1H, br s); 13C NMR (DMSO-d6, 125 MHz): δ 19.6, 23.8, 25.6, 36.7, 45.1, 53.4, 53.5, 107.9, 111.2, 111.3, 
1119.7, 122.7.7, 126.5, 128.2, 128.4, 129.1, 135.5, 136.4, 137.3, 167.3, 172.6, 175.9; LRMS (ES+) m/z: 
522.9 [M+Na]+; HRMS (ES+) calcd. for C24H23N2O5BrNa [M+Na]+ 521.0688, found 521.0686; [𝛼]!"#!"  -22.9 (c 
0.52, MeOH).  
(R)-6-bromo-9-(2-(((S)-1-carboxy-2-phenylethyl)amino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-
2-carboxylic acid (5m). The compound was prepared according to the method described for 5a from 3a 
(129 mg, 0.34 mmol), NH2-(L)-Phe-(OMe).HCl (84 mg, 0.39 mmol), 
HATU (163 mg, 0.43 mmol) and DIPEA (200 µL, 1.15 mmol) in dry DMF 
(1 mL). Global ester deprotection in an aqueous solution of NaOH (2 M; 
300 µL) and H2O:EtOH (1:1; 2 mL) gave 5m (98 mg, 57% yield) as a 
yellow solid: mp 208–210°C; 1H NMR (DMSO-d6, 500 MHz): δ 1.73–1.75 
(1H, m), 2.16 (1H, m), 2.59–2.60 (1H, m), 2.70–2.76 (3H, m), 2.87–2.93 
(2H, m), 3.08–3.11 (1H, m), 4.47–4.84 (1H, m, CH), 4.66–4.78 (2H, m), 
7.12–7.29 (7H, m), 7.53 (1H, s), 8.44–8.46 (1H, m), 12.63 (1H, br s); 13C 
NMR (DMSO-d6, 125 MHz): δ 19.6, 23.8, 25.7, 36.7, 39.4, 45.1, 53.3, 
107.9, 111.2, 111.3, 119.7, 122.7, 126.5, 128.2, 128.4, 129.1, 135.5, 136.5, 137.3, 167.3, 172.6, 175.9; 
LRMS (ES+) m/z: 521.0 [M+Na]+; HRMS (ES+) calcd. for C24H23N2O5BrNa [M+Na]+ 521.0688, found 
521.0710; [𝛼]!"#!"  +17.8 (c 0.48, MeOH). 
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